{"text": "( HealthDay)-Vitamin D deficiency ( VDD ) contributes to worse outcomes in elderly patients with diffuse large B - cell lymphoma ( DLBCL ) treated with rituximab , according to a study published online Aug. 18 in the Journal of ... .", "label": "", "metadata": {}, "score": "24.05303"}
{"text": "As life expectancy and the number of geriatric patients continue to rise , the incidence of diffuse large B - cell lymphoma ( DLBCL ) in the elderly will undoubtedly continue to increase as well .", "label": "", "metadata": {}, "score": "36.54316"}
{"text": "In diffuse large B - cell lymphoma ( DLBCL ) , the age - adjusted International Prognostic Index ( aaIPI ) score is currently used to predict patient outcomes and to choose the best therapeutic treatment .", "label": "", "metadata": {}, "score": "39.490803"}
{"text": "Together , these results suggest that low rather than high Ki-67 protein expression is of prognostic importance in DLBCL ... .High immunohistochemical expression of p - AKT predicts inferior survival in patients with diffuse large B - cell lymphoma treated with immunochemotherapy .", "label": "", "metadata": {}, "score": "40.60402"}
{"text": "T - cell / histiocyte - rich B - cell lymphoma ( T / HR ) has been categorized as a DLBCL , but it had been done with much controversy due to the ambiguous presentation of the malignancy .", "label": "", "metadata": {}, "score": "41.432423"}
{"text": "Alternatively , for older fit patients , a track record of successful trials has been established .In summary , further prospective clinical trials in very elderly patients with DLBCL are clearly needed .", "label": "", "metadata": {}, "score": "41.89691"}
{"text": "However none of these intensified regimens are appropriate for patients with comorbidities or with older age , and the survival results obtained with these current treatment options for patients with DLBCL indicate that new treatment modalities are needed .", "label": "", "metadata": {}, "score": "42.366264"}
{"text": "In addition , bcl-2 status could have prognostic importance also in the era of immunochemotherapy ... .Expression of CD68 + tumor - associated macrophages in patients with diffuse large B - cell lymphoma and its relation to prognosis .", "label": "", "metadata": {}, "score": "43.660187"}
{"text": "Interestingly , response to lenalidomide therapy was independent of the tumor burden , and of the number and the type of prior treatment .Compared to other type of lymphomas included ( mantle cell lymphoma , transformed large B - cell lymphoma , follicular lymphoma , grade III ) , progression - free survival ( PFS ) of the patients with DLBCL was the shortest . had substantially better results [ 53 ] .", "label": "", "metadata": {}, "score": "44.48484"}
{"text": "Although conventional cytogenetic methods such as Karyotypes and FISH have played a major role in classification schemes of lymphomas , better classification models are clearly needed to further understanding the biology , disease outcome and therapeutic management of DLBCL .", "label": "", "metadata": {}, "score": "45.711887"}
{"text": "Even if the natural history of DLBCL has been improved with treatments based on this association , there is clearly a need of improvement of long - term results .", "label": "", "metadata": {}, "score": "45.838554"}
{"text": "Relapsed or Refractory Diffuse Large B Cell Lymphoma .Intervention ICMJE .Drug : 131I - rituximab .Study Arm ( s ) .Experimental : 131I - rituximab .", "label": "", "metadata": {}, "score": "45.920273"}
{"text": "S4 , abstract 331a , 2011 .View at Google Scholar Assessment of tumor cell proliferation based on Ki-67 expression yielded conflicting prognostic predictions of patients with diffuse large B - cell lymphoma ( DLBCL ) .", "label": "", "metadata": {}, "score": "46.6659"}
{"text": "Latta and colleagues comprehensively summarize the existing data , leaving the reader with a practical guide on how to tailor treatment for the very elderly patient with DLBCL in the current era .", "label": "", "metadata": {}, "score": "47.133156"}
{"text": "However , the pathogenic association of MVDs and VEGF expression by tumor cell in DLBCL remain controversial [ 19 ] .On the basis of these results and on results on in vivo model [ 20 ] , it can be hypothesized that patients with DLBCL characterized by increased tumor MVD may benefit from antiangiogenic effect of lenalidomide [ 21 ] .", "label": "", "metadata": {}, "score": "47.492874"}
{"text": "View Article PubMed .Camilleri - Broet S : A uniform activated B - cell - like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas : analysis of 83 cases .", "label": "", "metadata": {}, "score": "47.812202"}
{"text": "Introduction .Diffuse large B - cell lymphoma ( DLBCL ) is the most common subtype of non - Hodgkin 's lymphomas , representing 30 % of all newly diagnosed cases and more than 80 % of aggressive lymphomas [ 1 ] .", "label": "", "metadata": {}, "score": "47.82975"}
{"text": "Among these include intravascular LBCL , EBV + DLBCL of the elderly , large B - cell lymphoma arising in HHV8 + multicentric Castleman disease , Lymphomatoid granulomatosis , LBCL with features intermediate between DLBCL and HL and PAL .", "label": "", "metadata": {}, "score": "48.340706"}
{"text": "Molecular profiles have identified most T / HR DLBCL cases to a subgroup of DLBCL distinguished by a \" host response \" with an adverse clinical outcome [ 53 ] .", "label": "", "metadata": {}, "score": "48.350098"}
{"text": "View Article PubMed .Franke S : Comparative genomic hybridization pattern distinguishes T - cell / histiocyte - rich B - cell lymphoma from nodular lymphocyte predominance Hodgkin 's lymphoma .", "label": "", "metadata": {}, "score": "48.65011"}
{"text": "In the literature , the relationship between BMI and cancer incidence has been frequently studied .A recent review suggested a relationship between the secretion of cytokines in obese adipose tissue and the development of a microenvironment favorable to cancer proliferation and aggressiveness [ 44 ] .", "label": "", "metadata": {}, "score": "48.708508"}
{"text": "The lack of correlation between the number of FOXP3 + cells and survival could possibly indicate that tumour - infiltrating T(regs ) are of less clinical importance in DLBCL .", "label": "", "metadata": {}, "score": "48.915752"}
{"text": "View Article PubMed .Gurbuxani S , Anastasi J , Hyjek E : Diffuse large B - cell lymphoma - more than a diffuse collection of large B cells : an entity in search of a meaningful classification .", "label": "", "metadata": {}, "score": "49.50441"}
{"text": "However , 75 % of such HLA - I deficient tumors have concomitant alterations of CD58 ( LFA3 ) expression leading to a potential defect in adhesion and activation of NK cells as it has been shown for LFA1/ICAM1 [ 31 ] .", "label": "", "metadata": {}, "score": "49.695183"}
{"text": "View Article PubMed .Shaffer AL , Rosenwald A , Staudt LM : Lymphoid malignancies : the dark side of B - cell differentiation .Nat Rev Immunol .", "label": "", "metadata": {}, "score": "50.023216"}
{"text": "View at Google Scholar .F. J. Hernandez - Ilizaliturri , G. Deeb , P. L. Zinzani et al . , \" Higher response to lenalidomide in relapsed / refractory diffuse large b - cell lymphoma in nongerminal center b - cell - like than in germinal center b - cell - like phenotype , \" Cancer , vol .", "label": "", "metadata": {}, "score": "50.155262"}
{"text": "26 , pp .3217 - 3222 , 2012 .View at Google Scholar Diffuse Large B - Cell Lymphoma in the Very Elderly : The Case for Refining Our Clinical Trials .", "label": "", "metadata": {}, "score": "50.377754"}
{"text": "Moreover , high Ki-67 expression was associated with poor EFS in the homogeneous population of patients with DLBCL receiving R - CHOP regimen .Thus , inclu- sion of Ki-67 expression as a prognostic factor for DLBCL should be considered in future clinical trials .", "label": "", "metadata": {}, "score": "50.384274"}
{"text": "Our data emphasize the need for a new risk stratification system for CLL patients ... .The expression of NK cell inhibitory receptors on cytotoxic T cells in B - cell chronic lymphocytic leukaemia ( B - CLL ) .", "label": "", "metadata": {}, "score": "50.43856"}
{"text": "Therefore , DLBCL patients with low SUVmax appear to progress more slowly and had better prognosis than those with high SUVmax .\" [ Show abstract ] [ Hide abstract ] ABSTRACT : The treatment of patients with diffuse large B cell lymphoma ( DLBCL ) would be greatly facilitated with a rapid method for determining prognosis that can be performed more easily and earlier than cytological or specific pathological examinations .", "label": "", "metadata": {}, "score": "50.58806"}
{"text": "C. Agostinelli , C. Mueller , S. Zeynalova , et al . , \" Evidence for rituximab ( R ) underdosing in subpopulations of elderly patients with DLBC : results of the RICOVER-60 study of the DSHNHL , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "50.730392"}
{"text": "6 , pp .462 - 466 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. S. Czuczman , J. M. Vose , T. E. Witzig et al . , \" The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non - Hodgkin lymphoma of distinct histological origin , \" British Journal of Haematology , vol .", "label": "", "metadata": {}, "score": "50.78074"}
{"text": "Median progression - free survival was 6.2 months versus 1.7 months .No difference in OS was yet observed .Conclusion .Lenalidomide is a promising drug in DLBCL in relapse as well as in front - line therapy .", "label": "", "metadata": {}, "score": "50.882736"}
{"text": "It is also difficult to extrapolate from data generated in younger DLBCL patients .Consequently , prospective randomized studies have been performed in older , fitter patients with DLBCL .", "label": "", "metadata": {}, "score": "50.986565"}
{"text": "These results were further explored in a study analysing 33 patients with transformed follicular lymphoma ( tFL ) , transformed chronic lymphocytic leukaemia / small lymphocytic lymphoma ( tCLL / SLL ) [ 55 ] .", "label": "", "metadata": {}, "score": "51.0993"}
{"text": "Investigating spontaneous B - cell lymphoma development in aging \u03b2 2m - deficient mice , Street et al .[29 ] have shown that NK cells are critical in innate immune surveillance of B - cell lymphomas .", "label": "", "metadata": {}, "score": "51.13626"}
{"text": "4 , pp .1183 - 1190 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. E. Davis , K. D. Brown , U. Siebenlist , and L. M. Staudt , \" Constitutive nuclear factor \u03ba B activity is required for survival of activated B cell - like diffuse large B cell lymphoma cells , \" Journal of Experimental Medicine , vol .", "label": "", "metadata": {}, "score": "51.339554"}
{"text": "118 , p. 1632 , 2011 , ASH Annual Meeting Abstracts .View at Google Scholar .L. Rigacci , F. Zaja , A. Fabbri , et al . , \" Lenalidomide administration in heavily pretreated patients with non hodgkin lymphoma - first report of the REVEAL study ( REVlimid effectiveness of administration in patients with lymphoma ) , \" Blood , vol .", "label": "", "metadata": {}, "score": "51.4205"}
{"text": "25 , pp .1937 - 1947 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Gratzinger , S. Zhao , R. J. Tibshirani et al . , \" Prognostic significance of VEGF , VEGF receptors , and microvessel density in diffuse large B cell lymphoma treated with anthracycline - based chemotherapy , \" Laboratory Investigation , vol . 88 , no . 1 , pp .", "label": "", "metadata": {}, "score": "51.50064"}
{"text": "Unfavorable prognostic of high MVD has been confirmed on tissue microarray ( TMA ) in CHOP [16 ] , and R - CHOP [17 ] treated DLBCL patients .", "label": "", "metadata": {}, "score": "51.592964"}
{"text": "Figure 3 : Phase I / II trial of Italian Lymphoma Foundation for elderly untreated DLBCL .Several studies with lenalidomide in association with standard treatment are ongoing in first line DLBCL patients .", "label": "", "metadata": {}, "score": "51.730946"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. E. Davis , K. D. Brown , U. Siebenlist , and L. M. Staudt , \" Constitutive nuclear factor \u03ba B activity is required for survival of activated B cell - like diffuse large B cell lymphoma cells , \" Journal of Experimental Medicine , vol .", "label": "", "metadata": {}, "score": "51.73182"}
{"text": "Therefore , future studies should aim on the copy number alterations in newly defined uncommon large B - cell lymphoma entities , such as EBV + DLBCL of the elderly , ALK positive DLBCL and LBCL arising in HHV8-associated multicentric castleman disease .", "label": "", "metadata": {}, "score": "51.815235"}
{"text": "These results emphasise the potential role of confounding factors in explaining the impact of low BMI or gender on survival .Those patients with a low BMI may die from causes not related to the lymphoma and/or from the complications of the treatment .", "label": "", "metadata": {}, "score": "51.958557"}
{"text": "6 , pp .462 - 466 , 2011 .View at Publisher \u00b7 View at Google Scholar .V. Ivanov , E. Tabouret , G. Chuto et al . , \" Rituximab - lenalidomide - dexamethasone induces complete and durable remission in relapsed refractory diffuse large B - cell non - Hodgkin lymphoma , \" Leukemia and Lymphoma , vol .", "label": "", "metadata": {}, "score": "52.069706"}
{"text": "The patient population analyzed in the present study exhibited a higher rate of extranodal site involve- ment and lower proportion of GCB subtype when com- pared with Western patients . contributed to the different outcomes seen upon multi- variate analysis , although the extranodal involvement or GCB subtype was not significant prognostic factors in the current study .", "label": "", "metadata": {}, "score": "52.113853"}
{"text": "Abstract .Diffuse large B - cell lymphoma ( DLBCL ) is the most common type of non - Hodgkin Lymphoma comprising of greater than 30 % of adult non - Hodgkin Lymphomas .", "label": "", "metadata": {}, "score": "52.150604"}
{"text": "10 , pp .1842 - 1847 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. S. Czuczman , A. J. Grillo - L\u00f3pez , B. Alkuzweny , R. Weaver , A. Larocca , and P. Mclaughlin , \" Prognostic factors for non - Hodgkin 's lymphoma patients treated with chemotherapy may not predict outcome in patients treated with rituximab , \" Leukemia and Lymphoma , vol .", "label": "", "metadata": {}, "score": "52.20407"}
{"text": "Table 3 : Response to lenalidomide in patients with diffuse large B - cell lymphoma in first - line treatment .Beside concomitant association of lenalidomide and R - chemotherapy , alternative way to administer lenalidomide in front - line is a strategy of maintenance therapy after an induction of R - CHOP .", "label": "", "metadata": {}, "score": "52.30729"}
{"text": "Moving forward , microarray analysis should be used in an integrative approach using aCGH , gene expression profiles , SNP arrays and next generation sequencing techniques to better categorize DLBCL subtypes .", "label": "", "metadata": {}, "score": "52.36437"}
{"text": "Various reasons have been proposed for the various CNA just mentioned above and immuno - chemoresistance .Despite these efforts to subdivide DLBCL , the relationship between the different classification schemes has not been adequately studied .", "label": "", "metadata": {}, "score": "52.45032"}
{"text": "View Article PubMed .Wang SS : Polymorphisms in DNA repair and one - carbon metabolism genes and overall survival in diffuse large B - cell lymphoma and follicular lymphoma .", "label": "", "metadata": {}, "score": "52.501305"}
{"text": "Reichard KK , McKenna RW , Kroft SH : ALK - positive diffuse large B - cell lymphoma : report of four cases and review of the literature .", "label": "", "metadata": {}, "score": "52.599953"}
{"text": "4 , pp .736 - 745 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Ngo , S.-W. Hee , L.-C. Lim et al . , \" Prognostic factors in patients with diffuse large B cell lymphoma : before and after the introduction of rituximab , \" Leukemia & Lymphoma , vol .", "label": "", "metadata": {}, "score": "52.711147"}
{"text": "10.1002/path.2399 .View Article PubMed .Montesinos - Rongen M , Siebert R , Deckert M : Primary lymphoma of the central nervous system : just DLBCL or not ?", "label": "", "metadata": {}, "score": "52.774666"}
{"text": "6 , pp .879 - 884 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Challa - Malladi , Y. K. Lieu , O. Califano et al . , \" Combined genetic inactivation of \u03b2 2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma , \" Cancer Cell , vol .", "label": "", "metadata": {}, "score": "52.881477"}
{"text": "Several factors support the feasibility of such studies in the near future .Increasing collaboration within cooperative groups is already facilitating clinical trials in disease subsets and specific age groups .", "label": "", "metadata": {}, "score": "52.952682"}
{"text": "16 , pp .5984 - 5992 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. Reddy , F. J. Hernandez - Ilizaliturri , G. Deeb et al . , \" Immunomodulatory drugs stimulate natural killer - cell function , alter cytokine production by dendritic cells , and inhibit angiogenesis enhancing the anti - tumour activity of rituximab in vivo , \" British Journal of Haematology , vol .", "label": "", "metadata": {}, "score": "52.95697"}
{"text": "36 - 45 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. H. Wiernik , I. S. Lossos , J. M. Tuscano et al . , \" Lenalidomide monotherapy in relapsed or refractory aggressive non - Hodgkin 's lymphoma , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "53.032425"}
{"text": "30 , pp .4952 - 4957 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. E. Witzig , J. M. Vose , P. L. Zinzani et al . , \" An international phase II trial of single - agent lenalidomide for relapsed or refractory aggressive B - cell non - Hodgkin 's lymphoma , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "53.03722"}
{"text": "30 , pp .4952 - 4957 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. E. Witzig , J. M. Vose , P. L. Zinzani et al . , \" An international phase II trial of single - agent lenalidomide for relapsed or refractory aggressive B - cell non - Hodgkin 's lymphoma , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "53.03722"}
{"text": "[ 1 ] DLBCL is no exception .Current data generated in elderly cancer patients are difficult to apply to DLBCL .Despite a growing number of investigations , most have been performed in patients with solid tumors .", "label": "", "metadata": {}, "score": "53.163704"}
{"text": "10.1101/gad.12.13.1953 .PubMed Central View Article PubMed .Steinbach D : ABCA3 as a possible cause of drug resistance in childhood acute myeloid leukemia .", "label": "", "metadata": {}, "score": "53.170948"}
{"text": "The impact of gender , age and patient selection on prognosis and outcome in diffuse large B - cell lymphoma - a population - based study .", "label": "", "metadata": {}, "score": "53.256172"}
{"text": "Page 2 . level and response ( 21 ) .The present investigation was carried out to determine the value of Ki-67 expression in predicting the prognosis of patients with DLBCL receiving rituximab plus CHOP chemotherapy .", "label": "", "metadata": {}, "score": "53.35404"}
{"text": "Introduction .Diffuse large B - cell lymphoma ( DLBCL ) is the most frequent non - Hodgkin lymphoma comprising of greater than 30 % of adult non - Hodgkin lymphomas in the West , and an even higher percent in developing countries [ 1 ] .", "label": "", "metadata": {}, "score": "53.358772"}
{"text": "Diffuse large B - cell lymphoma associated with chronic inflammation ( CI ) is a DLBCL associated with long lasting inflammation that is associated with EBV+ .", "label": "", "metadata": {}, "score": "53.41413"}
{"text": "In this study , localization of FOXP3 + cells within tumor , a feature that has been shown to impact their clinical value in solid tumor [ 48 ] , has not been evaluated .", "label": "", "metadata": {}, "score": "53.475895"}
{"text": "10.1038/nm0102 - 68 .View Article PubMed .Kramer MH : Clinical relevance of BCL2 , BCL6 , and MYC rearrangements in diffuse large B - cell lymphoma .", "label": "", "metadata": {}, "score": "53.496216"}
{"text": "2694 - 2702 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. Lech - Maranda , J. Bienvenu , F. Broussais - Guillaumot et al . , \" Plasma TNF- \u03b1 and IL-10 level - based prognostic model predicts outcome of patients with diffuse large B - cell lymphoma in different risk groups defined by the international prognostic index , \" Archivum Immunologiae et Therapiae Experimentalis , vol .", "label": "", "metadata": {}, "score": "53.574318"}
{"text": "Nearly all the studies of prognostic indicators in DLBCL , including the IPI , have been based on the clinical outcome following treatment with CHOP [ 7 ] .", "label": "", "metadata": {}, "score": "53.576332"}
{"text": "16 , pp .5984 - 5992 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. H. Wiernik , I. S. Lossos , J. M. Tuscano et al . , \" Lenalidomide monotherapy in relapsed or refractory aggressive non - Hodgkin 's lymphoma , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "53.692688"}
{"text": "Blood 1994;83:1460 - 6 .Sanchez E , Chacon I , Plaza MM , et al .Clinical outcome in diffuse large B - cell lymphoma is dependent on the rela- tionship between different cell - cycle regulator proteins .", "label": "", "metadata": {}, "score": "53.75441"}
{"text": "996 - 1001 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .N. Reddy , F. J. Hernandez - Ilizaliturri , G. Deeb et al . , \" Immunomodulatory drugs stimulate natural killer - cell function , alter cytokine production by dendritic cells , and inhibit angiogenesis enhancing the anti - tumour activity of rituximab in vivo , \" British Journal of Haematology , vol .", "label": "", "metadata": {}, "score": "53.76114"}
{"text": "View at Google Scholar .C. Gisselbrecht , N. Schmitz , N. Mounier , et al . , \" Rituximab maintenance therapy after autologous stem - cell transplantation in patients with relapsed CD20 + diffuse large B - cell lymphoma : final analysis of the collaborative trial in relapsed aggressive lymphoma , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "53.79163"}
{"text": "In conclusion , in the rituximab era , the aaIPI score remains the major predictor of outcome in DLBCL patients ; however , male gender and low BMI seem to impact outcome .", "label": "", "metadata": {}, "score": "53.94978"}
{"text": "131 - 141 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. G. Corral , P. A. J. Haslett , G. W. Muller et al . , \" Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF- \u03b1 , \" Journal of Immunology , vol .", "label": "", "metadata": {}, "score": "54.049614"}
{"text": "The selection criteria were the availability of paraffin - embedded tumor biopsies for IHC analysis and detailed information on treatment and followup .Patients with T - cell lymphoma or B - cell lymphoma other than DLBCL were excluded .", "label": "", "metadata": {}, "score": "54.051178"}
{"text": "Our results suggest that increased expression of KIR and CD94 on CTL in advanced stage B - CLL may potentially contribute to the impaired anti - tumour immune response in these patients ... .", "label": "", "metadata": {}, "score": "54.064133"}
{"text": "25 , pp .1937 - 1947 , 2002 .View at Publisher \u00b7 View at Google Scholar .W. H. Wilson , S.-H. Jung , P. Porcu et al . , \" A cancer and leukemia group B multi - center study of DA - EPOCH - rituximab in untreated diffuse large B - cell lymphoma with analysis of outcome by molecular subtype , \" Haematologica , vol .", "label": "", "metadata": {}, "score": "54.09809"}
{"text": "By multivariate analysis , the revised International Prognostics Index ( R - IPI ) and SUV(max ) at diagnosis were shown to predict longer PFS .", "label": "", "metadata": {}, "score": "54.133163"}
{"text": "These data indicate that the pro - tumor effect of TAM has limited clinical relevance in DLBCL patients , which could imply that therapeutic strategies aimed at enhancing their anti - tumor activity are of continuous clinical interest ... .", "label": "", "metadata": {}, "score": "54.195408"}
{"text": "View at Google Scholar .F. J. Hernandez - Ilizaliturri , N. Reddy , B. Holkova , E. Ottman , and M. S. Czuczman , \" Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "54.461716"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. M. Cardesa - Salzmann , L. Colomo , G. Gutierrez et al . , \" High microvessel density determines a poor outcome in patients with diffuse large B - cell lymphoma treated with rituximab plus chemotherapy , \" Haematologica , vol .", "label": "", "metadata": {}, "score": "54.570892"}
{"text": "78 - 86 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Monti , K. J. Savage , J. L. Kutok et al . , \" Molecular profiling of diffuse large B - cell lymphoma identifies robust subtypes including one characterized by host inflammatory response , \" Blood , vol .", "label": "", "metadata": {}, "score": "54.634808"}
{"text": "Cancer .Wilson WH , Gerecitano JF , Goy A , et al .The Bruton 's tyrosine kinase ( BTK ) inhibitor , ibrutinib ( PCI-32765 ) , has preferential activity in the ABC subtype of relapsed / refractory de novo diffuse large B - cell lymphoma ( DLBCL ) : interim results of a multicenter , open - label , phase 2 study .", "label": "", "metadata": {}, "score": "54.655224"}
{"text": "53 - 57 , 2013 .View at Publisher \u00b7 View at Google Scholar . U.J\u00e4ger , M. Fridrik , M. Zeitlinger , et al . , \" Rituximab serum concentrations during immuno - chemotherapy of follicular lymphoma correlate with patient gender , bone marrow infiltration and clinical response , \" Haematologica , vol .", "label": "", "metadata": {}, "score": "54.6604"}
{"text": "6 , pp .3653 - 3659 , 2004 .View at Google Scholar \u00b7 View at Scopus . A. Plonquet , C. Haioun , J. P. Jais et al . , \" Peripheral blood natural killer cell count is associated with clinical outcome in patients with aaIPI 2 - 3 diffuse large B - cell lymphoma , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "54.671967"}
{"text": "N Engl J Med 1993;329:987 - 94 .Cheson BD , Pfistner B , Juweid ME , et al .Revised response criteria for malignant lymphoma .", "label": "", "metadata": {}, "score": "54.801132"}
{"text": "10.1016/S0002 - 9440(10)64462 - 8 .PubMed Central View Article PubMed .Monti S : Molecular profiling of diffuse large B - cell lymphoma identifies robust subtypes including one characterized by host inflammatory response .", "label": "", "metadata": {}, "score": "54.968666"}
{"text": "In the last decades , an important role to predict the outcome in DLBCL was represented by gene expression profiling and by pattern of origin , germinal center B - cell and nongerminal , or activated B - cell - like .", "label": "", "metadata": {}, "score": "55.019875"}
{"text": "Med Oncol 2001;18:15 - 22 .Determann O , Hoster E , Ott G , et al .Ki-67 predicts out- come in advanced - stage mantle cell lymphoma patients treated with anti - CD20 immunochemotherapy : results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group .", "label": "", "metadata": {}, "score": "55.079803"}
{"text": "10.1084/jem.20031074 .PubMed Central View Article PubMed .Savage KJ : The molecular signature of mediastinal large B - cell lymphoma differs from that of other diffuse large B - cell lymphomas and shares features with classical Hodgkin lymphoma .", "label": "", "metadata": {}, "score": "55.111526"}
{"text": "CAN-03 - 4056 .View Article PubMed .Miwa H : DNA sequences of the immunoglobulin heavy chain variable region gene in pyothorax - associated lymphoma .", "label": "", "metadata": {}, "score": "55.166496"}
{"text": "2006 , 12 ( 14 Pt 1 ) : 4357 - 4363 .View Article PubMed .Pasqualucci L : Hypermutation of multiple proto - oncogenes in B - cell diffuse large - cell lymphomas .", "label": "", "metadata": {}, "score": "55.282375"}
{"text": "View Article PubMed .Lenz G : Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell - like diffuse large B cell lymphoma .", "label": "", "metadata": {}, "score": "55.346306"}
{"text": "Broyde A , Boycov O , Strenov Y , Okon E , Shpilberg O , Bairey O. Role and prognostic significance of the Ki-67 index in non - Hodgkin 's lymphoma .", "label": "", "metadata": {}, "score": "55.38288"}
{"text": "A large international trial ( NCT01197560 ) to compare lenalidomide to investigator 's choice is still ongoing ; in this clinical study patients will be risk - stratified according to germinal center / nongerminal center B - cell - like in order to identify the subgroup that benefit from lenalidomide treatment .", "label": "", "metadata": {}, "score": "55.41159"}
{"text": "4284 - 4289 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. H. Wilson , K. Dunleavy , S. Pittaluga et al . , \" Phase II study of dose - adjusted EPOCH and rituximab in untreated diffuse large B - cell lymphoma with analysis of germinal center and post - germinal center biomarkers , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "55.449867"}
{"text": "This type of lymphoma is characterized by clinical and morphological features that overlap between DLBCL , particularly primary mediastinal large B - cell lymphoma , and classic Hodgkin lymphoma .", "label": "", "metadata": {}, "score": "55.49353"}
{"text": "45 - 57 , 2013 .View at Google Scholar .K. R. Carson , N. L. Bartlett , J. R. McDonald , et al . , \" Increased body mass index is associated with improved survival in United States veterans with diffuse large B - cell lymphoma , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "55.5372"}
{"text": "36 , pp .4462 - 4469 , 2012 .View at Google Scholar . A. M. Carella , C. A. de Souza , S. Luminari , et al . , \" Prognostic role of gender in diffuse large B - cell lymphoma treated with rituximab containing regimens : a Fondazione Italiana Linfomi / Grupo de Estudos em Mol\u00e9stias Onco - Hematol\u00f3gicas retrospective study , \" Leukemia & Lymphoma , vol .", "label": "", "metadata": {}, "score": "55.597576"}
{"text": "It is clinically heterogeneous and includes a wide spectrum of lymphoid neoplasms .Many morphological , biological , cytogenetics and clinical studies have attempted to subdivide DLBCL into morphological variants , molecular , immunophenotypic subgroups , and distinct disease entities .", "label": "", "metadata": {}, "score": "55.694584"}
{"text": "This review revealed oncogenic pathways that are used differentially by the DLBCL subtypes , reinforcing the view that they represent pathogenetically distinct diseases .Declarations .", "label": "", "metadata": {}, "score": "55.74289"}
{"text": "In fact , Kreisel et al .[ 27 ] showed 9p21.3 band region as chemoresistant in DLBCL .Large B - cell lymphoma ( LBCL ) associated with epstein - barr virus and/or kaposi sarcoma - associated herpesvirus / human herpesvirus 8 .", "label": "", "metadata": {}, "score": "55.755035"}
{"text": "These results support previously described GC - like properties of LBCLB , particularly that of better clinical outcome , 1q gain and 2p16.1 amplifications .DLBCL of the central nervous system .", "label": "", "metadata": {}, "score": "55.792583"}
{"text": "Many clinical studies have demonstrated that the poor outcome of ABC - like DLBCL might relate to the constitutive activation of the nuclear factor kappa \u03b2 pathway [ 18 , 19 ] .", "label": "", "metadata": {}, "score": "55.79273"}
{"text": "View at Google Scholar . U.Vitolo , A. Chiappella , A. M. Carella , et al . , \" Lenalidomide plus Rituximab - CHOP21 in elderly diffuse large B - cell lymphoma ( DLBCL ) : results of phase I part of REAL07 trial of Italian Lymphoma Foundation ( FIL ) , \" Annals of Oncology , vol .", "label": "", "metadata": {}, "score": "55.81578"}
{"text": "4 , pp .314 - 322 , 2004 .View at Google Scholar \u00b7 View at Scopus . A. Rosenwald , G. Wright , W. C. Chan et al . , \" The use of molecular profiling to predict survival after chemotherapy for diffuse large - B - cell lymphoma , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "55.825382"}
{"text": "Lenz G : Molecular subtypes of diffuse large B - cell lymphoma arise by distinct genetic pathways .Proc Natl Acad Sci U S A. 2008 , 105 ( 36 ) : 13520 - 13525 .", "label": "", "metadata": {}, "score": "55.832687"}
{"text": "The percentage of Ki-67-expressing cells reflects the proportion of actively replicating tumor cells .The prognostic significance of Ki-67 staining in DLBCL is currently a controversial issue ( 8) .", "label": "", "metadata": {}, "score": "55.94165"}
{"text": "10.1182/blood-2005 - 07 - 2950 .PubMed Central View Article PubMed .Rinaldi A : Comparative genome - wide profiling of post - transplant lymphoproliferative disorders and diffuse large B - cell lymphomas .", "label": "", "metadata": {}, "score": "56.013847"}
{"text": "Official Title ICMJE .A Phase II Study of 131I - rituximab for Elderly or Poor Performance Status Patients With Diffuse Large B Cell Lymphoma ( DLBCL ) or for Adult Patients With Relapsed or Refractory DLBCL .", "label": "", "metadata": {}, "score": "56.162262"}
{"text": "The advantage in treatment with lenalidomide seems to be increased in nongerminal subtype compared to germinal subgroup ; this hypothesis should be based on the different expression of NF- .", "label": "", "metadata": {}, "score": "56.201744"}
{"text": "S. E. A. Street , Y. Hayakawa , Y. Zhan et al . , \" Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and \u03b3 \u03b4 T cells , \" Journal of Experimental Medicine , vol .", "label": "", "metadata": {}, "score": "56.212223"}
{"text": "10.1038/sj.leu.2404919 .View Article PubMed .Said J : Diffuse aggressive B - cell lymphomas .Adv Anat Pathol .10.1097/PAP.0b013e3181a9d5d2 .", "label": "", "metadata": {}, "score": "56.25637"}
{"text": "This variation has been described with other monoclonal antibodies [ 27 - 32 ] .One explanation for the changes in pharmacokinetics with hormonal variation and the slower elimination of monoclonal antibodies observed in women could be an inhibition of antibody production and/or uptake for degradation by oestrogen alpha receptor stimulation [ 33 - 36 ] .", "label": "", "metadata": {}, "score": "56.290222"}
{"text": "View at Google Scholar .N. Murawski , G. Held , S. Zeynalova , et al . , \" Improved outcome of elderly DLBCL patients with 6xCHOP-14 and 8 rituximab applications given over an extended period ( SMARTE - R - CHOP-14 DSHNHL trial ) is due to better results of male patients , \" Haematologica , vol .", "label": "", "metadata": {}, "score": "56.358566"}
{"text": "792 - 801 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Z. Harris , S. M. Tsunoda , P. Mroczkowski , H. Wong , and L. Z. Benet , \" The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics , \" Clinical Pharmacology and Therapeutics , vol .", "label": "", "metadata": {}, "score": "56.38467"}
{"text": "143 - 149 , 2012 .View at Publisher \u00b7 View at Google Scholar .P. L. Zinzani , A. Broccoli , V. Stefoni et al . , \" Immunophenotype and intermediate - high international prognostic index score are prognostic factors for therapy in diffuse large B - cell lymphoma patients , \" Cancer , vol .", "label": "", "metadata": {}, "score": "56.40426"}
{"text": "124 - 128 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. M\u00fcller , N. Murawski , M. H. J. Wiesen et al . , \" The role of sex and weight on rituximab clearance and serum elimination half - life in elderly patients with DLBCL , \" Blood , vol .", "label": "", "metadata": {}, "score": "56.442978"}
{"text": "Seki R , Okamura T , Koga H , et al .Prognostic signifi- cance of the F - box protein Skp2 expression in diffuse large B - cell lymphoma .", "label": "", "metadata": {}, "score": "56.62526"}
{"text": "Ki-67 in DLBCL treated with R - CHOP \u00aa 2010 John Wiley & Sons A / S 153 .Page 6 . resulting in a higher relapse rate , as Ki-67 expression is associated with tumor aggressiveness and poor progno- sis in a variety of malignancies ( 31 ) .", "label": "", "metadata": {}, "score": "56.659393"}
{"text": "275 - 282 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Galustian , B. Meyer , M. C. Labarthe et al . , \" The anti - cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells , \" Cancer Immunology , Immunotherapy , vol .", "label": "", "metadata": {}, "score": "56.684074"}
{"text": "1622 - 1627 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. J. Hernandez - Ilizaliturri , G. Deeb , P. L. Zinzani et al . , \" Higher response to lenalidomide in relapsed / refractory diffuse large b - cell lymphoma in nongerminal center b - cell - like than in germinal center b - cell - like phenotype , \" Cancer , vol .", "label": "", "metadata": {}, "score": "56.7023"}
{"text": "The gene is usually involved with the following translocations : t(2 ; 17)(p23;q23 ) or t(2:5)(p23;q35 ) .This type of lymphoma is a rare entity constituting only less than 1 % of DLBCL cases .", "label": "", "metadata": {}, "score": "56.795017"}
{"text": "It is unclear what genes in these regions are functionally important in the pathogenesis of PMBL .Of note , genes that were more frequently up - regulated in these regions were JAK-2 and T - cell inhibitor ligand PD - L2 .", "label": "", "metadata": {}, "score": "56.854126"}
{"text": "However , only 1p35.1 - 1p36.12 , 1q21.1 - 1q23.1 and 1p36.11 - 1p36.33 were unique to PL when compared with DLBCL ( AIDS related and non - AIDS related ) and plasma cell myeloma .", "label": "", "metadata": {}, "score": "56.857697"}
{"text": "11 , pp .4930 - 4935 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Seki , K. Ohshima , T. Fujisaki et al . , \" Prognostic impact of immunohistochemical biomarkers in diffuse large B - cell lymphoma in the rituximab era , \" Cancer Science , vol .", "label": "", "metadata": {}, "score": "56.86221"}
{"text": "5 , pp .379 - 391 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. Dall'Ozzo , S. Tartas , G. Paintaud et al . , \" Rituximab - dependent cytotoxicity by natural killer cells : influence of FCGR3A polymorphism on the concentration - effect relationship , \" Cancer Research , vol .", "label": "", "metadata": {}, "score": "56.930176"}
{"text": "C. M. Ng , R. Bruno , D. Combs , and B. Davies , \" Population pharmacokinetics of rituximab ( anti - CD20 monoclonal antibody ) in rheumatoid arthritis patients during a phase II clinical trial , \" Journal of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "56.944798"}
{"text": "19 , pp .3121 - 3127 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .O. Fitoussi , K. Belhadj , N. Mounier et al . , \" Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high - risk diffuse large B - cell lymphoma for GELA , \" Haematologica , vol .", "label": "", "metadata": {}, "score": "56.97696"}
{"text": "Some recent reports have focused on the impact of gender or BMI on the outcomes of patients with DLBCL [ 15 - 20 ] , but this question has never been addressed in a large cohort of patients previously included in prospective trials and uniformly treated with rituximab .", "label": "", "metadata": {}, "score": "57.046936"}
{"text": "17 , pp .1625 - 1638 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. A. Jones , L. E. Fayad , L. S. Elting , and M. A. Rodriguez , \" Body mass index and outcomes in patients receiving chemotherapy for intermediate - grade B - cell non - Hodgkin lymphoma , \" Leukemia & Lymphoma , vol .", "label": "", "metadata": {}, "score": "57.17575"}
{"text": "The availability of oncologists with specific geriatric training to provide input into trial protocol design may increase enrollment of older patients and ensure successful trial completion .", "label": "", "metadata": {}, "score": "57.235744"}
{"text": "10.3960/jslrt.46.1 .View Article PubMed .Oyama T : Senile EBV+B - cell lymphoproliferative disorders : a clinicopathologic study of 22 patients .Am J Surg Pathol .", "label": "", "metadata": {}, "score": "57.255054"}
{"text": "The advent of microarray - based studies ( chromosome , RNA , gene expression , etc ) has provided a plethora of high - resolution data that could potentially facilitate the finer classification of DLBCL .", "label": "", "metadata": {}, "score": "57.323303"}
{"text": "10.1038/modpathol.3800742 .View Article PubMed .Shimoyama Y : Senile Epstein - Barr virus - associated B - cell lymphoproliferative disorders : a mini review .", "label": "", "metadata": {}, "score": "57.376183"}
{"text": "Discussion .DLBCL is a heterogeneous disease , as the microarray analysis showed that patients with DLBCL expressing a gene expression profile ( GEP ) of germinal center B cells ( GCB ) have a longer survival than patients of activated B cells ( ABC ) [ 10 ] .", "label": "", "metadata": {}, "score": "57.43164"}
{"text": "10.1007/s00428 - 008 - 0593-x .View Article PubMed .Dijkman R : Array - based comparative genomic hybridization analysis reveals recurrent chromosomal alterations and prognostic parameters in primary cutaneous large B - cell lymphoma .", "label": "", "metadata": {}, "score": "57.45423"}
{"text": "The association with Fc \u03b3 RIII polymorphisms and clinical outcome has been used to argue for an ADCC mechanism of action of rituximab in vivo , but the association is less significant in DLBCL [ 40 ] than initially report in follicular lymphoma [ 41 ] .", "label": "", "metadata": {}, "score": "57.48638"}
{"text": "1830 - 1840 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Koivula , E. Valo , A. Raunio , S. Hautaniemi , and S. Lepp\u00e4 , \" Rituximab regulates signaling pathways and alters gene expression associated with cell death and survival in diffuse large B - cell lymphoma , \" Oncology Reports , vol .", "label": "", "metadata": {}, "score": "57.512474"}
{"text": "275 - 282 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Rosenwald , G. Wright , W. C. Chan , et al . , \" The use of molecular profiling to predict survival after chemotherapy for diffuse large - B - cell lymphoma , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "57.606354"}
{"text": "Hunt KE , Reichard KK .Diffuse large B - cell lymphoma .Arch Pathol Lab Med 2008;132:118 - 24 .Mounier N , Briere J , Gisselbrecht C , et al .", "label": "", "metadata": {}, "score": "57.643074"}
{"text": "Studies testing single novel agents or non - myelosupressive combinations may be most appropriate for the very elderly .An ongoing clinical trial designed for less fit elderly Hodgkin lymphoma patients is testing single - agent brentuximab vedotin ( Adcetris ) as first - line therapy in those not fit to receive standard ABVD ( Adriamycin [ doxorubicin ] , bleomycin , vinblastine , dacarbazine ) .", "label": "", "metadata": {}, "score": "57.65683"}
{"text": "CO;2-I. View Article PubMed .Wessendorf S : Automated screening for genomic imbalances using matrix - based comparative genomic hybridization .Lab Invest .", "label": "", "metadata": {}, "score": "57.661804"}
{"text": "18 , pp .4117 - 4126 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. H. Wilson , K. Dunleavy , S. Pittaluga et al . , \" Phase II study of dose - adjusted EPOCH and rituximab in untreated diffuse large B - cell lymphoma with analysis of germinal center and post - germinal center biomarkers , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "57.686897"}
{"text": "5 , pp .1851 - 1861 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. M. Habermann , S. S. Wang , M. J. Maurer et al . , \" Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B - cell lymphoma patients in the pre - rituximab era , \" Blood , vol .", "label": "", "metadata": {}, "score": "57.70133"}
{"text": "C. P. Hans , D. D. Weisenburger , T. C. Greiner et al . , \" Confirmation of the molecular classification of diffuse large B - cell lymphoma by immunohistochemistry using a tissue microarray , \" Blood , vol .", "label": "", "metadata": {}, "score": "57.77201"}
{"text": "[ 7 ] While these results are very useful , further investigations are needed , since population studies in this group , reflecting outcomes in the general population , appear even more inferior .", "label": "", "metadata": {}, "score": "57.772057"}
{"text": "PubMed .Rosenwald A : Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma .", "label": "", "metadata": {}, "score": "57.777702"}
{"text": "Diffuse Large B - cell Lymphomas ( DLBCL ) are the most frequent Non - Hodgkin Lymphomas ( NHL ) .The addition of Rituximab to the standard chemotherapy CHOP improved the outcome in this patients , but so far 40 % of patients experienced relapse or progressive disease .", "label": "", "metadata": {}, "score": "57.792046"}
{"text": "5 , pp .779- 786 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. B. Saltz , S. Clarke , E. D\u00edaz - Rubio , et al . , \" Bevacizumab in combination with oxaliplatin - based chemotherapy as first - line therapy in metastatic colorectal cancer : a randomized phase III study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "57.85229"}
{"text": "However ; one limitation is the inability to detect balanced chromosome translocations .Nonetheless , aCGH can facilitate new construct classifiers for DLBCL subtypes .Other key technology worth mentioning that may provide classification models for DLBCL include single nucleotide polymorphism ( SNP ) arrays .", "label": "", "metadata": {}, "score": "58.03686"}
{"text": "Tumor cells positive for the markers were evaluated semiquantitatively with a cutoff of 30 % .Treatment Response and Survival Evaluation .The response criterion of non - Hodgkin 's lymphomas was applied to determine the occurrence of complete remission ( CR ) , partial remission ( PR ) , stable disease ( SD ) , or progressive disease ( PD ) .", "label": "", "metadata": {}, "score": "58.061577"}
{"text": "10.1182/blood-2005 - 03 - 1024 .View Article PubMed .Belaud - Rotureau MA : Inactivation of p16INK4a / CDKN2A gene may be a diagnostic feature of large B cell lymphoma leg type among cutaneous B cell lymphomas .", "label": "", "metadata": {}, "score": "58.097946"}
{"text": "12 , pp .1861 - 1874 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Hayashi , T. Hideshima , M. Akiyama et al . , \" Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells : clinical application , \" British Journal of Haematology , vol .", "label": "", "metadata": {}, "score": "58.10013"}
{"text": "The most common reasons for dose reduction were neutropenia ( 56 % ) and thrombocytopenia ( 31 % ) [ 53 ] .Table 2 : Grade III - IV toxicities with lenalidomide as monotherapy in relapsed / refractory DLBCL .", "label": "", "metadata": {}, "score": "58.159912"}
{"text": "It is likely that advances in molecular biology will allow the current classification to be augmented , with the recognition of newer entities and the homogenization of lymphoma subtypes .", "label": "", "metadata": {}, "score": "58.17086"}
{"text": "PubMed .Davis RE : Constitutive nuclear factor kappaB activity is required for survival of activated B cell - like diffuse large B cell lymphoma cells .", "label": "", "metadata": {}, "score": "58.231293"}
{"text": "Based on these actions , lenalidomide represented an active drug on aggressive relapsed NHL .In this review , the most relevant clinical trials for the use of lenalidomide in DLBCL were reported .", "label": "", "metadata": {}, "score": "58.308296"}
{"text": "426 - 431 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Joosse , S. Collette , S. Suciu , et al . , \" Superior outcome of women with stage I / II cutaneous melanoma : pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "58.42982"}
{"text": "View Article PubMed .Wlodarska I : FOXP1 , a gene highly expressed in a subset of diffuse large B - cell lymphoma , is recurrently targeted by genomic aberrations .", "label": "", "metadata": {}, "score": "58.43187"}
{"text": "Survival Analysis and Response to Treatment .To evaluate the prognostic efficacy of the three factors , we performed survival analyses based on the individual markers alone and in combination .", "label": "", "metadata": {}, "score": "58.508255"}
{"text": "In terms of clinical outcome , PMBL is now more favorable due to intensive chemotherapy and radiation therapy [ 44 ] .Further investigation is needed to see whether these regions can be used to distinguish PMBL from cHD .", "label": "", "metadata": {}, "score": "58.58531"}
{"text": "Other retrospective studies reported the impact of gender on the outcomes of patients treated with rituximab and chemotherapy for DLBCL or follicular lymphoma [ 15 , 25 ] .", "label": "", "metadata": {}, "score": "58.638138"}
{"text": "1622 - 1627 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. L. Zinzani , C. Pellegrini , L. Gandolfi et al . , \" Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B - cell lymphoma : a phase 2 trial , \" Clinical Lymphoma , Myeloma and Leukemia , vol .", "label": "", "metadata": {}, "score": "58.712463"}
{"text": "1758 - 1760 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. S. Czuczman , J. M. Vose , T. E. Witzig et al . , \" The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non - Hodgkin lymphoma of distinct histological origin , \" British Journal of Haematology , vol .", "label": "", "metadata": {}, "score": "58.799255"}
{"text": "5 , pp .758 - 765 , 2012 .View at Publisher \u00b7 View at Google Scholar .K. Gu , D. D. Weisenburger , K. Fu et al . , \" Cell of origin fails to predict survival in patients with diffuse large B - cell lymphoma treated with autologous hematopoietic stem cell transplantation , \" Hematological Oncology , vol .", "label": "", "metadata": {}, "score": "58.808704"}
{"text": "Additionally , imaging and therapy agents can be co - delivered to provide seamless integration of diagnostics , therapy , and follow - up , and different therapeutic modalities such as chemotherapy and hyperthermia can be co - administered to take advantage of synergistic effects .", "label": "", "metadata": {}, "score": "58.818863"}
{"text": "1431 - 1438 , 2012 .View at Google Scholar .I. Ord\u00e1s , D. R. Mould , B. G. Feagan , and W. J. Sandborn , \" Anti - TNF monoclonal antibodies in inflammatory bowel disease : pharmacokinetics - based dosing paradigms , \" Clinical Pharmacology and Therapeutics , vol .", "label": "", "metadata": {}, "score": "58.87079"}
{"text": "Haematologica .10.3324/haematol.2010.033126 .PubMed Central View Article PubMed .Thunberg U : Genetic variation in tumor necrosis factor and risk of diffuse large B - cell lymphoma and follicular lymphoma : differences between subgroups in Swedish patients .", "label": "", "metadata": {}, "score": "58.912655"}
{"text": "10.1182/blood-2003 - 06 - 1841 .View Article PubMed .Savage KJ : Primary mediastinal large B - cell lymphoma .Oncologist .10.1634/theoncologist.11 - 5 - 488 .", "label": "", "metadata": {}, "score": "58.925014"}
{"text": "Response to Lenalidomide in Relapsed / Refractory DLBCL .Data emerging from early clinical trials demonstrated that lenalidomide has a significant activity against relapsed / refractory DLBCL either as monotherapy or as an association with rituximab .", "label": "", "metadata": {}, "score": "58.930458"}
{"text": "22 , pp .2313 - 2323 , 2008 .View at Publisher \u00b7 View at Google Scholar .W. W. L. Choi , D. D. Weisenburger , T. C. Greiner et al . , \" A new immunostain algorithm classifies diffuse large B - cell lymphoma into molecular subtypes with high accuracy , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "58.976757"}
{"text": "View Article PubMed .Booman M : Genomic alterations and gene expression in primary diffuse large B - cell lymphomas of immune - privileged sites : the importance of apoptosis and immunomodulatory pathways .", "label": "", "metadata": {}, "score": "59.02334"}
{"text": "View Article PubMed .Bea S : Diffuse large B - cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene - expression - based survival prediction .", "label": "", "metadata": {}, "score": "59.0317"}
{"text": "22 , pp .5058 - 5066 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. L. Zinzani , C. Pellegrini , L. Gandolfi et al . , \" Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B - cell lymphoma : a phase 2 trial , \" Clinical Lymphoma , Myeloma and Leukemia , vol .", "label": "", "metadata": {}, "score": "59.097702"}
{"text": "4284 - 4289 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . \" A predictive model for aggressive non - Hodgkin 's lymphoma .", "label": "", "metadata": {}, "score": "59.1232"}
{"text": "View Article PubMed .Takakuwa T : Establishment and characterization of unique cell lines derived from pyothorax - associated lymphoma which develops in long - standing pyothorax and is strongly associated with Epstein - Barr virus infection .", "label": "", "metadata": {}, "score": "59.13738"}
{"text": "9759 , pp .42 - 51 , 2011 .View at Publisher \u00b7 View at Google Scholar .J. L. Villano , M. Koshy , H. Shaikh , T. A. Dolecek , and B. J. McCarthy , \" Age , gender , and racial differences in incidence and survival in primary CNS lymphoma , \" British Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "59.21795"}
{"text": "192 - 203 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. K. Hsu , H. Quach , T. Tai et al . , \" The immunostimulatory effect of lenalidomide on NK - cell function is profoundly inhibited by concurrent dexamethasone therapy , \" Blood , vol .", "label": "", "metadata": {}, "score": "59.22442"}
{"text": "PubMed Central PubMed .Harada S : Molecular and immunological dissection of diffuse large B cell lymphoma : CD5 + , and CD5- with CD10 + groups may constitute clinically relevant subtypes .", "label": "", "metadata": {}, "score": "59.232975"}
{"text": "Immunohistochemistry Study .Formalin - fixed , paraffin - embedded tumor sections were examined for the expression of CD10 , BCL-6 , and MUM1 .Briefly , slides were deparaffinized by xylene and rehydrated .", "label": "", "metadata": {}, "score": "59.282253"}
{"text": "Hasselblom S , Ridell B , Sigurdardottir M , Hansson U , Nilsson - Ehle H , Andersson PO .Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B - cell lymphoma .", "label": "", "metadata": {}, "score": "59.29484"}
{"text": "Hall PA , Richards MA , Gregory WM , d'Ardenne AJ , Lister TA , Stansfeld AG .The prognostic value of Ki67 immunostaining in non - Hodgkin 's lymphoma .", "label": "", "metadata": {}, "score": "59.300507"}
{"text": "Table 1 : Characteristics of DLBCL patients treated with CHOP or R - CHOP .Immunohistochemistry Results .The expression patterns of CD10 , BCL-6 , and MUM1 among the patients treated with CHOP and R - CHOP are summarized in Tables 2 and 3 .", "label": "", "metadata": {}, "score": "59.342945"}
{"text": "Array CGH and gene expression profiles identify molecular subtypes .In 2008 , Lenz et al .[ 2 ] analyzed 203 DLBCL samples by high resolution array CGH and gene expression profile to investigate the 3 molecular subtypes of DLBCL .", "label": "", "metadata": {}, "score": "59.38651"}
{"text": "An earlier investigation found no association between Ki-67 expression in DLBCL and response rate to rituximab plus chemotherapy ( 21 ) .However , the cited study was small in size , involving only 15 patients with DLBCL , and survival was not included as an endpoint .", "label": "", "metadata": {}, "score": "59.42447"}
{"text": "In both groups , the median OS was not reached .Bcl-2 expression and subtype of DLBCL ( GCB vs. non - GCB ) were not prognostic for either EFS or OS .", "label": "", "metadata": {}, "score": "59.43415"}
{"text": "4664 - 4669 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Ahlgrimm , M. Pfreundschuh , M. Kreuz , E. Regitz , K.-D. Preuss , and J. Bittenbring , \" The impact of Fc- \u03b3 receptor polymorphisms in elderly patients with diffuse large B - cell lymphoma treated with CHOP with or without rituximab , \" Blood , vol .", "label": "", "metadata": {}, "score": "59.455326"}
{"text": "Therefore , relying on these data , it is too early to consider a gender- or BMI - specific therapeutic approach in DLBCL .Conflict of Interests .", "label": "", "metadata": {}, "score": "59.474464"}
{"text": "Blood 2003;101:4279 - 84 .Winter JN , Weller EA , Horning SJ , et al .Prognostic sig- nificance of Bcl-6 protein expression in DLBCL treated with CHOP or R - CHOP : a prospective correlative study .", "label": "", "metadata": {}, "score": "59.527798"}
{"text": "In first - line therapy with conventional CHOP , which has been the standard chemotherapy regimen for DLBCL for more than two decades , patients within the GCB group have a better 5-year survival than patients within the non - GCB subgroup [ 4 ] .", "label": "", "metadata": {}, "score": "59.66255"}
{"text": "14 , pp .4650 - 4657 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .Z. Z. Yang , A. J. Novak , M. J. Stenson , T. E. Witzig , and S. M. Ansell , \" Intratumoral CD4 + CD25 + regulatory T - cell - mediated suppression of infiltrating CD4 + T cells in B - cell non - Hodgkin lymphoma , \" Blood , vol .", "label": "", "metadata": {}, "score": "59.665165"}
{"text": "10.1182/blood .V99.3.815 .View Article PubMed .Tagawa H : Genome - wide array - based comparative genomic hybridization of diffuse large B - cell lymphoma : comparison between CD5-positive and CD5-negative cases .", "label": "", "metadata": {}, "score": "59.737072"}
{"text": "As in the present analysis , the CORAL study reported an effect of BMI on the impact of gender .Indeed , in their study , young women or slim women seemed to benefit more from rituximab maintenance salvage after ASCT than did men or overweighted postmenopausal women .", "label": "", "metadata": {}, "score": "59.759396"}
{"text": "The activity of lenalidomide in histological subtypes at poor outcome , like in activated B - cell DLBCL , may be demonstrated in prospective trials .", "label": "", "metadata": {}, "score": "59.766785"}
{"text": "Third , the interpretation of our data might be limited by short follow - up period with high censoring rate although our study could demonstrate the significance of Ki-67 index even with the low number of events .", "label": "", "metadata": {}, "score": "59.82997"}
{"text": "10.1182/blood-2004 - 07 - 2947 .View Article PubMed .Matolcsy A , Chadburn A , Knowles DM : De novo CD5-positive and Richter 's syndrome - associated diffuse large B cell lymphomas are genotypically distinct .", "label": "", "metadata": {}, "score": "59.86841"}
{"text": "The role of lenalidomide as salvage therapy in both cell of origin patterns in DLBCL ( germinal center B - cell / activated B - cell ) was reported in preliminary data .", "label": "", "metadata": {}, "score": "59.878075"}
{"text": "As men had lower PFS and OS than women , it seems important that gender perspective be taken into account in future studies ... .Low rather than high Ki-67 protein expression is an adverse prognostic factor in diffuse large B - cell lymphoma .", "label": "", "metadata": {}, "score": "59.88717"}
{"text": "Patients are unresponsive to rituximab and have a poor clinical outcome [ 72 ] .EBV + DLBCL of the elderly .Epstein - Barr virus - positive DLBCL of the elderly is a newly recognized subtype of DLBCL by the WHO classification ( 2008 ) which presents as an EBV + clonal B - cell proliferation usually in patients over 50 years [ 1 , 73 , 74 ] .", "label": "", "metadata": {}, "score": "59.892326"}
{"text": "The aim of our study was to identify whether cell - of - origin distinction has prognostic impact on DLBCL patients treated with combination of rituximab and chemotherapy .", "label": "", "metadata": {}, "score": "59.91198"}
{"text": "View Article PubMed .Tagawa H : Comparison of genome profiles for identification of distinct subgroups of diffuse large B - cell lymphoma .Blood .", "label": "", "metadata": {}, "score": "59.933212"}
{"text": "10.1016/j.cancergen.2010.12.010 .View Article PubMed .Perez - Rosado A : BCL6 represses NFkappaB activity in diffuse large B - cell lymphomas .J Pathol .", "label": "", "metadata": {}, "score": "59.995987"}
{"text": "Abstract .Diffuse large B - cell lymphoma ( DLBCL ) is the most common form of non - Hodgkin 's lymphoma ( NHL ) in adults .", "label": "", "metadata": {}, "score": "60.042233"}
{"text": "The introduction of rituximab in therapeutic arsenal has greatly changed the clinical course of DLBCL [ 6 , 37 , 38 ] .Beside natural cytotoxicity mentioned above , NK cell may be involved in Rituximab mediated antidody dependant cytotoxicity ( ADCC ) by the engagement of the Fc portion of the antibody on their Fc \u03b3 RIII ( CD16 ) receptors .", "label": "", "metadata": {}, "score": "60.076263"}
{"text": "Patients from the LNH03 - 2B study were younger and exhibited lower aaIPI scores .There were no differences in B symptoms or bulk mass rates between the 3 trials .", "label": "", "metadata": {}, "score": "60.08638"}
{"text": "Geng H : Virtual CGH : an integrative approach to predict genetic abnormalities from gene expression microarray data applied in lymphoma .BMC Med Genomics .", "label": "", "metadata": {}, "score": "60.099327"}
{"text": "PubMed Central View Article PubMed .Cesarman E , Mesri EA : Kaposi sarcoma - associated herpesvirus and other viruses in human lymphomagenesis .Curr Top Microbiol Immunol .", "label": "", "metadata": {}, "score": "60.104744"}
{"text": "Some progress on the understanding of DLBCL physiopathology enables us to speculate on biological pathways that could be targeted by lenalidomide ( Figure 1 ) .", "label": "", "metadata": {}, "score": "60.140236"}
{"text": "These patients also more frequently exhibited low albumin levels or high creatinine levels compared with the other patients ( data not shown ) , promoting a higher rate of complications and treatment - related toxicities .", "label": "", "metadata": {}, "score": "60.201027"}
{"text": "In a recent study , Hernandez - Ilizaliturri retrospectively analyzed clinical outcomes of 40 patients with relapsed / refractory DLBCL , 23 germinal center , and 17 nongerminal center , treated with salvage lenalidomide as single agent .", "label": "", "metadata": {}, "score": "60.209244"}
{"text": "Monoclonal antibody therapy for B - cell non - Hodgkin 's lymphoma .N Engl J Med 2008;359:613 - 26 .Scholzen T , Gerdes J. The Ki-67 protein : from the known and the unknown .", "label": "", "metadata": {}, "score": "60.232468"}
{"text": "Diffuse large B - cell lymphoma ( DLBCL ) can be molecularly subtyped as either germinal center B - cell ( GCB ) or non - GCB .", "label": "", "metadata": {}, "score": "60.23561"}
{"text": "However , the correlation between FOXP3 + infiltrating T cells and prognosis has been subsequently evaluated independently in GC and non - GC DLBCL subgroups [ 46 ] , as defined by Hans algorithm [ 47 ] .", "label": "", "metadata": {}, "score": "60.243614"}
{"text": "Hans CP , Weisenburger DD , Greiner TC , et al . Confirma- tion of the molecular classification of diffuse large B - cell lymphoma by immunohistochemistry using a tissue micro- array .", "label": "", "metadata": {}, "score": "60.28681"}
{"text": "In line with previous Western clinical studies [ 12 , 13 ] , our data demonstrate that addition of rituximab to chemotherapy improves the outcome of DLBCL patients of all ages and risk groups in China .", "label": "", "metadata": {}, "score": "60.3288"}
{"text": "10.1038/sj.leu.2401487 .View Article PubMed .Yamaguchi M : De novo CD5 + diffuse large B - cell lymphoma : a clinicopathologic study of 109 patients .", "label": "", "metadata": {}, "score": "60.383972"}
{"text": "Blood .View Article .Godde - Salz E , Feller AC , Lennert K : Chromosomal abnormalities in lymphogranulomatosis X ( LgrX)/angioimmunoblastic lymphadenopathy ( AILD ) .", "label": "", "metadata": {}, "score": "60.404762"}
{"text": "Very little is known about the genetic aberrations associated with this malignancy .Unclassifiable types .LBCL with features intermediate between DLBCL and Burkitt lymphoma .", "label": "", "metadata": {}, "score": "60.555084"}
{"text": "287 - 295 , 2012 .View at Publisher \u00b7 View at Google Scholar . A. V. Patel , W. R. Diver , L. R. Teras , B. M. Birmann , and S. M. Gapstur , \" Body mass index , height , and risk of lymphoid neoplasms in a large US cohort , \" Leukemia & Lymphoma , vol .", "label": "", "metadata": {}, "score": "60.583504"}
{"text": "6 , pp .728 - 740 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. F. Barber , M. Faure , and E. O. Long , \" LFA-1 contributes an early signal for NK cell cytotoxicity , \" Journal of Immunology , vol .", "label": "", "metadata": {}, "score": "60.592285"}
{"text": "Indeed , PCBCL is associated with the ABC DLBCL molecular subtype and requires therapy intensification [ 50 ] .Large B - cell lymphoma specified by histology , phenotype , or genotype .", "label": "", "metadata": {}, "score": "60.59843"}
{"text": "462 - 469 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Delarue , H. Tilly , G. Salles , et al . , \" R - CHOP14 compared to R - CHOP21 in elderly patients with diffuse large B - cell lymphoma ( DLBCL ) : final analysis of the LNH03 - 6B GELA study , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "60.654305"}
{"text": "Clinical outcomes defined immunohistologically as GCB versus non - GCB subtypes are shown in Figures 1(a ) and 1(b ) .The survival rate in the CHOP group was significantly better for the GCB subtype than for the non - GCB subtype ( Figure 1(c ) ) .", "label": "", "metadata": {}, "score": "60.710266"}
{"text": "Likewise , genomic losses were detected in 1p36.32 , 6q21 , 8p23.3 , 9p21.3 and 17p13.1 .Of note , by concentrating on the gain of 13q21 - 34 and loss of 1p34 - 36 , Tagawa et al . was also able to recognize prognostically distinct subgroups within the CD5 + DLBCL subset .", "label": "", "metadata": {}, "score": "60.79244"}
{"text": "9806 , pp .1858 - 1867 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. B. Bartlett , K. Dredge , and A. G. Dalgleish , \" The evolution of thalidomide and its IMiD derivatives as anticancer agents , \" Nature Reviews Cancer , vol .", "label": "", "metadata": {}, "score": "60.856663"}
{"text": "View Article PubMed .Hummel M : A biologic definition of Burkitt 's lymphoma from transcriptional and genomic profiling .N Engl J Med .10.1056/NEJMoa055351 .", "label": "", "metadata": {}, "score": "60.876877"}
{"text": "5 , pp .379 - 391 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. M. Habermann , E. A. Weller , V. A. Morrison et al . , \" Rituximab - CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B - cell lymphoma , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "60.88748"}
{"text": "De novo , CD5 + large B - cell lymphoma .DLBCL expresses a variety of B - cell surface markers including CD5 in approximately 10 % of cases [ 54 ] .", "label": "", "metadata": {}, "score": "60.9982"}
{"text": "Immunoglobulin genes in PAL are usually clonally rearranged and usually TP53 mutations can be seen [ 58 , 59 ] .PAL is usually a precursor to DLBCL associated with chronic inflammation [ 10 ] .", "label": "", "metadata": {}, "score": "61.04596"}
{"text": "91 - 100 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. A. Gilbert and J. M. Slingerland , \" Cytokines , obesity , and cancer : new insights on mechanisms linking obesity to cancer risk and progression , \" Annual Review of Medicine , vol .", "label": "", "metadata": {}, "score": "61.06658"}
{"text": "PubMed .Barth TF : Gains of 2p involving the REL locus correlate with nuclear c - Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma .", "label": "", "metadata": {}, "score": "61.091026"}
{"text": "11 , pp .3909 - 3918 , 1997 .View at Google Scholar \u00b7 View at Scopus .C. Percy , G. O'Conor , L. G. Ries , and E. S. Jaffe , \" Non - Hodgkin 's lymphomas .", "label": "", "metadata": {}, "score": "61.1774"}
{"text": "411 - 442 , 2012 .View at Publisher \u00b7 View at Google Scholar .N. A. Dobbs , C. J. Twelves , H. Gillies , C. A. James , P. G. Harper , and R. D. Rubens , \" Gender affects doxorubicin pharmacokinetics in patients with normal liver biochemistry , \" Cancer Chemotherapy and Pharmacology , vol .", "label": "", "metadata": {}, "score": "61.25493"}
{"text": "The treatment scheme is described in Figure 3 .At the end of phase I part of the trial , MTD for lenalidomide in association with R - CHOP21 resulted as 15 mg days 1 - 15 .", "label": "", "metadata": {}, "score": "61.336887"}
{"text": "In conclusion , male gender and low BMI may impact outcomes in DLBCL .The main message of this analysis is that based on large prospective data , gender or BMI may influence the outcomes of DLBCL patients treated with R - CHOP in the context of other confounding factors .", "label": "", "metadata": {}, "score": "61.3694"}
{"text": "By the Cox proportional hazards regression model , in the CHOP group , the IHC - defined GCB phenotypes and clinical characters such as males , young patients , and early stages were associated with a significantly favorable survival rate , independently of other IPI parameters .", "label": "", "metadata": {}, "score": "61.389534"}
{"text": "16 , pp .2717 - 2724 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Nyman , M. Adde , M. L. Karjalainen - Lindsberg et al . , \" Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B - cell lymphoma patients treated with immunochemotherapy , \" Blood , vol .", "label": "", "metadata": {}, "score": "61.40222"}
{"text": "In this model , the augmentation of TNF \u03b1 is due to production by both CD4 + and CD8 + T cells , and is dependent on IL2-mediated signalling .", "label": "", "metadata": {}, "score": "61.415356"}
{"text": "References .REFERENCES .Dale W , Mohile SG , Eldadah BA , et al .Biological , clinical , and psychosocial correlates at the interface of cancer and aging research .", "label": "", "metadata": {}, "score": "61.458363"}
{"text": "DLBCL is the most frequent type of NHL .The outcome of DLBCL has been remarkably improved in younger as well as elderly patients by rituximab , a chimeric monoclonal antibody targeting the CD20 antigen .", "label": "", "metadata": {}, "score": "61.507538"}
{"text": "36 - 45 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Lu , F. Payvandi , L. Wu et al . , \" The anti - cancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions , \" Microvascular Research , vol .", "label": "", "metadata": {}, "score": "61.526417"}
{"text": "Swerdlow SH , Campo E , Harris NL , Jaffe ES , Pileri SA , Stein H , Thiele J , Vardiman JW .WHO classification of tumours haematopoietic and lymphoid tissues .", "label": "", "metadata": {}, "score": "61.530594"}
{"text": "Owing to the insufficient availability of histologic sections , immunostaining could not be performed for CD10 , bcl-6 , or MUM1 in eight patients and for bcl-2 in 41 patients .", "label": "", "metadata": {}, "score": "61.61767"}
{"text": "Saito B , Shiozawa E , Usui T , et al .Rituximab with chemotherapy improves survival of non - germinal center type untreated diffuse large B - cell lymphoma .", "label": "", "metadata": {}, "score": "61.683273"}
{"text": "The immunomodulatory agent lenalidomide ( Revlimid ) and the Bruton tyrosine kinase inhibitor ibrutinib have demonstrated notable single - agent efficacy in DLBCL .[ 9,10 ] Since the elderly are more likely to be diagnosed with the activated B - cell subtype of DLBCL , these agents may be particularly suited for study in this population , given their activity in this subgroup and their limited toxicity profile .", "label": "", "metadata": {}, "score": "61.75326"}
{"text": "Numerous cytogenetic studies including karyotypes and fluorescent in situ hybridization ( FISH ) , as well as morphological , biological , clinical , microarray and sequencing technologies have attempted to categorize DLBCL into morphological variants , molecular and immunophenotypic subgroups , as well as distinct disease entities .", "label": "", "metadata": {}, "score": "61.77437"}
{"text": "N Engl J Med .10.1056/NEJMoa012914 .View Article PubMed .Shipp MA : Diffuse large B - cell lymphoma outcome prediction by gene - expression profiling and supervised machine learning .", "label": "", "metadata": {}, "score": "61.797768"}
{"text": "Acknowledgment .U. Vitolo is supported by Advisory Committee of Roche Italy .Lecture - fee of Celgene and Janssen - Cilag .References . F. D. Groves , M. S. Linet , L. B. Travis , and S. S. Devesa , \" Cancer surveillance series : non - Hodgkin 's lymphoma incidence by histologic subtype in the United States from 1978 through 1995 , \" Journal of the National Cancer Institute , vol .", "label": "", "metadata": {}, "score": "61.895382"}
{"text": "28 , no .27 , pp . 4184- 4190 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. Gaidarova , D. Mendy , C. Heise , et al . , \" Lenalidomide induces capping of CD20 and cytoskeleton proteins to enhance rituximab immune recognition of malignant B - cells , \" Blood , vol .", "label": "", "metadata": {}, "score": "62.15487"}
{"text": "This is by no means a deficiency in the accompanying article but rather reflects the lack of prospectively collected clinical trial data guiding treatment of our oldest patients .", "label": "", "metadata": {}, "score": "62.161026"}
{"text": "High Ki-67 expression was associated with shorter OS and EFS , and higher relapse rates , consistent with previous data from the non - rituximab era on a prospective analysis of DLBCL ( 11 ) , and mantle cell lymphoma treated with a ritux- imab - containing regimen ( 20 ) .", "label": "", "metadata": {}, "score": "62.219456"}
{"text": "Conclusions .The introduction of IMiDs in the treatment of DLBCL represented an improvement in the outcome of this patients .Lenalidomide represents a manageable drug , with good results in relapsed or refractory DLBCL patients heavily pretreated .", "label": "", "metadata": {}, "score": "62.257095"}
{"text": "17 , pp .5494 - 5502 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Feugier , A. Van Hoof , C. Sebban et al . , \" Long - term results of the R - CHOP study in the treatment of elderly patients with diffuse large B - cell lymphoma : a study by the groupe d'etude des lymphomes de l'adulte , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "62.316113"}
{"text": "In fact , the most recent World Health Organization ( WHO ) classification published in 2008 groups most of these lymphomas into the category of DLBCL , not otherwise specified ( DLBCL - NOS ) [ 4 ] .", "label": "", "metadata": {}, "score": "62.317066"}
{"text": "89 , no .11 , pp .3909 - 3918 , 1997 .View at Google Scholar \u00b7 View at Scopus .C. P. Hans , D. D. Weisenburger , T. C. Greiner et al . , \" Confirmation of the molecular classification of diffuse large B - cell lymphoma by immunohistochemistry using a tissue microarray , \" Blood , vol .", "label": "", "metadata": {}, "score": "62.37938"}
{"text": "ECM : extracellular matrix components .MVD : microvascular density .Antiangiogenic Effects .Beside the two biologically and clinically distinct GC and ABC molecular subtypes of DLBCL defined by a tumoral cell signature [ 4 , 15 ] , different stromal gene signatures have been linked to prognosis [ 5 , 15 ] .", "label": "", "metadata": {}, "score": "62.423634"}
{"text": "However , strong p53 protein expression was corre- lated with p53 mutations , and prognostic significance for DLBCL patients treated with R - CHOP was maintained ( 29 ) .", "label": "", "metadata": {}, "score": "62.432163"}
{"text": "View Article PubMed .Ferreri AJ : Anthracycline - based chemotherapy as primary treatment for intravascular lymphoma .Ann Oncol .10.1093/annonc / mdh274 .", "label": "", "metadata": {}, "score": "62.466484"}
{"text": "Array - based CGH provides high resolution genome wide measurement of DNA copy number alterations highlighting patterns of deletions and amplifications .An additional advantage of array - based CGH is the assessment of allelic ratio or loss of heterozygosity .", "label": "", "metadata": {}, "score": "62.477623"}
{"text": "( HealthDay)-Newly approved anticancer drugs that do not have a specific molecular target on cancer cells are associated with increased toxicity and the accompanying costs of management , according to research published online ... .", "label": "", "metadata": {}, "score": "62.48462"}
{"text": "Therefore , we confirmed that the addition of R to standard chemotherapy showed a proof - of - survival benefit in the present study .Subclassification on the Basis of the Cell of Origin Is Predictive of Survival in Patients with DLBCL Who Were Treated with CHOP but Not with R - CHOP .", "label": "", "metadata": {}, "score": "62.527916"}
{"text": "4 , pp .429 - 435 , 1996 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .O. Schmetzer and A. Fl\u00f6rcken , \" Sex differences in the drug therapy for oncologic diseases , \" Handbook of Experimental Pharmacology , no .", "label": "", "metadata": {}, "score": "62.608315"}
{"text": "5 , pp .1605 - 1613 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. M. Habermann , E. A. Weller , V. A. Morrison et al . , \" Rituximab - CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B - cell lymphoma , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "62.655098"}
{"text": "Progression - free survival ( PFS ) was determined as an interval between the date of diagnosis and relapse , or death .The relationships between the three markers , the subdivision and OS were assessed by Kaplan - Meier graphs .", "label": "", "metadata": {}, "score": "62.73531"}
{"text": "4 , pp .635 - 646 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Jilma - Stohlawetz , R. A. Reiter , S. Panzer , M. Horvath , W. Eppel , and B. Jilma , \" Pharmacokinetics ( PK ) of S / D treated anti - D immunoglobulin after intramuscular injection in healthy volunteers : gender differences in PK , \" Transfusion and Apheresis Science , vol .", "label": "", "metadata": {}, "score": "62.749435"}
{"text": "These biological analyses have been able not only to capture the molecular heterogeneity of tumor cells [ 4 ] , but also to demonstrate the existence of a complex interaction between the tumor and its microenvironnement involving multiple signaling pathways and regulatory mechanisms [ 5 ] .", "label": "", "metadata": {}, "score": "62.754414"}
{"text": "Direct Effect on Tumor Cells .A hallmark of ABC DLBCL is the constitutive activation of the NF \u03ba B pathway , on which they rely for survival and proliferation [ 34 ] .", "label": "", "metadata": {}, "score": "62.873474"}
{"text": "Results showed that 25 mg was considered as the recommended dose .Most frequent adverse event was grade 3 - 4 neutropenia in 59 % , including 7 % of febrile neutropenia , and grade 3 - 4 thrombocytopenia in 30 % .", "label": "", "metadata": {}, "score": "62.90101"}
{"text": "Full - text \u00b7 Article \u00b7 Sep 2011 \u00b7 Applied biochemistry and biotechnology .The ALC was measured just before and on day + 21 after R - CHOP in 230 consecutive patients with stage I and II DLBCL .", "label": "", "metadata": {}, "score": "63.016342"}
{"text": "5 , pp .1857 - 1861 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Lenz , G. Wright , S. S. Dave et al . , \" Stromal gene signatures in large - B - cell lymphomas , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "63.02269"}
{"text": "10.1182/blood-2002 - 08 - 2577 .View Article PubMed .Wessendorf S : Further delineation of chromosomal consensus regions in primary mediastinal B - cell lymphomas : an analysis of 37 tumor samples using high - resolution genomic profiling ( array - CGH ) .", "label": "", "metadata": {}, "score": "63.038177"}
{"text": "Habermann TM , Weller EA , Morrison VA , et al .Rituximab - CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B - cell lymphoma .", "label": "", "metadata": {}, "score": "63.054745"}
{"text": "In this study , the advantage in PFS provided by the rituximab was smaller in men than in women [ 22 ] .The authors also reported that men but not women might benefit from extended rituximab exposure [ 23 ] .", "label": "", "metadata": {}, "score": "63.197624"}
{"text": "10.1002/gcc.10016 .View Article PubMed .Green MR : Integrative analysis reveals selective 9p24.1 amplification , increased PD-1 ligand expression , and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B - cell lymphoma .", "label": "", "metadata": {}, "score": "63.275623"}
{"text": "Beside effects on microenvironment , lenalidomide has been shown to have a direct effect on DLBCL cell lines , with a decrease in NF \u03ba B activity and an arrest in DNA synthesis [ 51 ] .", "label": "", "metadata": {}, "score": "63.278324"}
{"text": "19 , pp .3121 - 3127 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Pfreundschuh , L. Tr\u00fcmper , A. \u00d6sterborg et al . , \" CHOP - like chemotherapy plus rituximab versus CHOP - like chemotherapy alone in young patients with good - prognosis diffuse large - B - cell lymphoma : a randomised controlled trial by the MabThera International Trial ( MInT ) Group , \" Lancet Oncology , vol .", "label": "", "metadata": {}, "score": "63.330498"}
{"text": "Mohile S , Dale W , Hurria A. Geriatric oncology research to improve clinical care .Nat Rev Clin Oncol .Peyrade F , Jardin F , Thieblemont C , et al .", "label": "", "metadata": {}, "score": "63.342026"}
{"text": "2226 - 2229 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Tilly , E. Lepage , B. Coiffier et al . , \" Intensive conventional chemotherapy ( ACVBP regimen ) compared with standard CHOP for poor - prognosis aggressive non - Hodgkin lymphoma , \" Blood , vol .", "label": "", "metadata": {}, "score": "63.342888"}
{"text": "1649 - 1657 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. Hasselblom , B. Ridell , H. Nilsson - Ehle , and P.-O. Andersson , \" The impact of gender , age and patient selection on prognosis and outcome in diffuse large B - cell lymphoma - a population - based study , \" Leukemia & Lymphoma , vol .", "label": "", "metadata": {}, "score": "63.36902"}
{"text": "A similar study by Montesinos et al .[ 48 ] reported similar findings .DLBCL of the CNS is predominately of the molecular ABC subtype , thus explaining the poor prognosis of this subset of DLBCL [ 49 ] .", "label": "", "metadata": {}, "score": "63.404156"}
{"text": "View Article PubMed .Worrillow L : Polymorphisms in the nucleotide excision repair gene ERCC2/XPD and risk of non - Hodgkin lymphoma .Cancer Epidemiol .", "label": "", "metadata": {}, "score": "63.458538"}
{"text": "17 , pp .4657 - 4662 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Wu , M. Adams , T. Carter et al . , \" Lenalidomide enhances natural killer cell and monocyte - mediated antibody - dependent cellular cytotoxicity of rituximab - treated CD20 + tumor cells , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "63.570503"}
{"text": "View Article .Steven S , Nancy Lee H , Elaine J , Harald S , Jurgen T , James V , A. Pileri S , C E : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues .", "label": "", "metadata": {}, "score": "63.588425"}
{"text": "View Article PubMed .Chang CC : Genomic profiling of plasmablastic lymphoma using array comparative genomic hybridization ( aCGH ) : revealing significant overlapping genomic lesions with diffuse large B - cell lymphoma .", "label": "", "metadata": {}, "score": "63.60089"}
{"text": "Although proportion of patients with GCB subtype was higher in the high Ki-67 group , significance of Ki-67 was still maintained in the multivariate analysis which was performed with multiple variables including subtypes of DLBCL .", "label": "", "metadata": {}, "score": "63.656235"}
{"text": "In contrast , constitutive activation of the nuclear factor kB pathway is a distinctive feature of both the ABC and primary mediastinal B - cell lymphoma ( PMBL ) subtype [ 16 - 19 ] .", "label": "", "metadata": {}, "score": "63.66405"}
{"text": "In a recent study including a proportion of patients treated with rituximab containing regimens , Ki-67 could provide further prognos- tic information in patients with a low International Prog- nostic Index ( IPI ) or bulky disease ( 13 ) .", "label": "", "metadata": {}, "score": "63.792114"}
{"text": "Several studies have suggested that prognostic factors for patients with non - Hodgkin 's lymphoma have changed for those treated with rituximab , and patient characteristics may differ between those treated with chemotherapy or rituximab .", "label": "", "metadata": {}, "score": "63.80589"}
{"text": "Diffuse large B cell lymphoma ( DLBCL ) is the most common type of non - Hodgkin lymphoma in Korea .Although there is standard therapy , which is called ' R - CHOP ' , many obstacles to use aggressive cytotoxic chemotherapeutic agents such as old age , poor performance status , refractoriness , and relapsed disease still remains .", "label": "", "metadata": {}, "score": "63.88427"}
{"text": "Introduction .Diffuse large B - cell lymphoma ( DLBCL ) represents roughly 40 % of all non - Hodgkin lymphoma ( NHL ) ( Figure 1 ) , with a rate of incidence in continuous increase and median age at diagnosis of 55 - 60 years [ 1 , 2 ] .", "label": "", "metadata": {}, "score": "63.8929"}
{"text": "Gerdes J , Lemke H , Baisch H , Wacker HH , Schwab U , Stein H. Cell cycle analysis of a cell proliferation - associ- ated human nuclear antigen defined by the monoclonal antibody Ki-67 .", "label": "", "metadata": {}, "score": "63.958954"}
{"text": "pas.0000126781.87158 . e3 .View Article PubMed .Du MQ , Bacon CM , Isaacson PG : Kaposi sarcoma - associated herpesvirus / human herpesvirus 8 and lymphoproliferative disorders .", "label": "", "metadata": {}, "score": "63.960045"}
{"text": "135 - 140 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J.-F. Lu , R. Bruno , S. Eppler , W. Novotny , B. Lum , and J. Gaudreault , \" Clinical pharmacokinetics of bevacizumab in patients with solid tumors , \" Cancer Chemotherapy and Pharmacology , vol .", "label": "", "metadata": {}, "score": "64.0029"}
{"text": "Introduction .The incidence of non - Hodgkin 's lymphoma ( NHL ) has been increasing worldwide during the last 40 years and accounts for 4 % of all cancer diagnoses .", "label": "", "metadata": {}, "score": "64.09212"}
{"text": "Bentz M : Gain of chromosome arm 9p is characteristic of primary mediastinal B - cell lymphoma ( MBL ) : comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line .", "label": "", "metadata": {}, "score": "64.10608"}
{"text": "Action on Proinflammatory Cytokines and T - cell Activation .Consistent with the signature of an ongoing inflammatory / immune response , HR tumors had increased expression of interferon - induced genes , tumor necrosis family ( TNF ) ligands and receptors , cytokine receptors , adhesion molecules , and extracellular matrix components .", "label": "", "metadata": {}, "score": "64.1501"}
{"text": "Panel B illustrates common CNA for all subtypes .Commonalities were highlighted if three or more subtypes had a CNA at that particular band region .", "label": "", "metadata": {}, "score": "64.165115"}
{"text": "Extrahematological toxicities included tumor flares in 7 patients , 4 ( 1.8 % ) with grade 1 or 2 and 3 with grade 3 , gastrointestinal events in 61.3 % , rash in 18 % and fatigue in 28 % .", "label": "", "metadata": {}, "score": "64.19177"}
{"text": "Zhang A , Ohshima K , Sato K , Kanda M , Suzumiya J , Shimazaki K , Kawasaki C , Kikuchi M. Prognostic clinico- pathologic factors , including immunologic expression in diffuse large B - cell lymphomas .", "label": "", "metadata": {}, "score": "64.26163"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. J. Hernandez - Ilizaliturri , N. Reddy , B. Holkova , E. Ottman , and M. S. Czuczman , \" Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model , \" Clinical Cancer Research , vol .", "label": "", "metadata": {}, "score": "64.296364"}
{"text": "The table below summarizes genomic gains and losses for the various DLBCL subtypes , Table 2 - , Figure 1 - .Amplification of 8q24 listed here in PAL was detected by classical CGH and southern blot analysis .", "label": "", "metadata": {}, "score": "64.29717"}
{"text": "View Article PubMed .Ohshima K : Chromosomal and comparative genomic analyses of HHV-8-negative primary effusion lymphoma in five HIV - negative Japanese patients .", "label": "", "metadata": {}, "score": "64.34772"}
{"text": "Lenalidomide : Clinical Experience and New Options in Untreated DLBCL .The promising results of lenalidomide in relapsed / refractory DLBCL setting , encouraged the development of trial with this drug in first line treatment .", "label": "", "metadata": {}, "score": "64.369934"}
{"text": "Action on Regulatory T Cells . , defined as CD4 + CD25 + T cells , play an important role in the immune system , not only by inhibiting autoimmunity , but also by hampering the antitumour response [ 43 ] .", "label": "", "metadata": {}, "score": "64.431885"}
{"text": "Carbone PP , Kaplan HS , Musshoff K , Smithers DW , Tubiana M. Report of the Committee on Hodgkin 's Disease Staging Classification .Cancer Res 1971;31 : 1860 - 1 .", "label": "", "metadata": {}, "score": "64.44858"}
{"text": "9806 , pp .1858 - 1867 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Tilly , E. Lepage , B. Coiffier et al . , \" Intensive conventional chemotherapy ( ACVBP regimen ) compared with standard CHOP for poor - prognosis aggressive non - Hodgkin lymphoma , \" Blood , vol .", "label": "", "metadata": {}, "score": "64.50013"}
{"text": "Tolerance seems acceptable and long term results of the recently published trials should in the future help to define the place of this drug in the therapeutic strategy of patients with DLBCL .", "label": "", "metadata": {}, "score": "64.58575"}
{"text": "6 , pp .1221 - 1227 , 2013 .View at Publisher \u00b7 View at Google Scholar .S. Riihij\u00e4rvi , M. Taskinen , M. Jerkeman , and S. Lepp\u00e4 , \" Male gender is an adverse prognostic factor in B - cell lymphoma patients treated with immunochemotherapy , \" European Journal of Haematology , vol .", "label": "", "metadata": {}, "score": "64.59711"}
{"text": "In young patients affected by poor prognosis DLBCL at diagnosis , rituximab plus dose - dense chemotherapy plus high - dose chemotherapy and autologous stem cell transplant were tested , with promising results ( 4-year PFS 73 % and 4-year OS 80 % ) [ 6 ] .", "label": "", "metadata": {}, "score": "64.64437"}
{"text": "4 , pp .235 - 242 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. Coiffier , C. Thieblemont , E. Van Den Neste et al . , \" Long - term outcome of patients in the LNH-98.5 trial , the first randomized study comparing rituximab - CHOP to standard CHOP chemotherapy in DLBCL patients .", "label": "", "metadata": {}, "score": "64.68033"}
{"text": "Table 1 : Response to Lenalidomide in relapsed / refractory diffuse large B - cell lymphomas .The first phase II trial was a single - arm , multicenter trial ( NHL002 ) that evaluates the safety and efficacy of lenalidomide oral monotherapy ( 25 mg / day during 21 days every 28 days ) in 49 patients with relapsed or refractory aggressive NHL [ 52 ] .", "label": "", "metadata": {}, "score": "64.702484"}
{"text": "15 , pp .1240 - 1251 , 2000 .View at Google Scholar \u00b7 View at Scopus .J. O. Armitage , \" A clinical evaluation of the International Lymphoma Study Group classification of non - Hodgkin 's lymphoma , \" Blood , vol .", "label": "", "metadata": {}, "score": "64.84689"}
{"text": "These studies complied with all provisions of the Declaration of Helsinki and its current amendments and were conducted in accordance with Good Clinical Practice guidelines .", "label": "", "metadata": {}, "score": "64.887054"}
{"text": "Authors ' Contribution .C. Thieblemont and M.-H. Delfau - Larue have contributed equally to this paper .References .The Non - Hodgkin 's Lymphoma Classification Project , \" A clinical evaluation of the International Lymphoma Study Group classification of non - Hodgkin 's lymphoma , \" Blood , vol .", "label": "", "metadata": {}, "score": "64.94052"}
{"text": "View Article .Joos S : Primary mediastinal ( thymic ) B - cell lymphoma is characterized by gains of chromosomal material including 9p and amplification of the REL gene .", "label": "", "metadata": {}, "score": "64.98152"}
{"text": "Lenalidomide : Clinical Experience in Relapsed / Refractory DLBCL .On the basis of the invivo activity of IMiDs , Wiernik et al . conducted a phase II multicenter trial to evaluate safety and efficacy of lenalidomide monotherapy in relapsed / refractory aggressive lymphomas patients .", "label": "", "metadata": {}, "score": "65.01953"}
{"text": "12 , pp .1877 - 1881 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Tilly , F. Morschhauser , G. A. Salles , et al . , \" Phase I study of escalating doses of lenalidomide combined with R - CHOP ( R2-CHOP ) for front - line treatment of B - cell lymphomas , \" Blood , vol .", "label": "", "metadata": {}, "score": "65.029495"}
{"text": "The expression patterns of the three proteins were similar in the two groups .We successfully grouped all patients into GCB or non - GCB subtypes .", "label": "", "metadata": {}, "score": "65.06792"}
{"text": "In line with other studies , the main problem in our study was the poor methodological standardization due to nonuniform technology .Prospective studies would obtain more reliable information than retrospective studies .", "label": "", "metadata": {}, "score": "65.09767"}
{"text": "Multivariate analyses were performed with a Cox proportional hazards regression model .Among the different clinical correlations , we paid specific attention to the interaction between BMI and gender , as this interaction stood out among the literature data .", "label": "", "metadata": {}, "score": "65.11283"}
{"text": "Colomo L , Lopez - Guillermo A , Perales M , Rives S , Mar- tinez A , Bosch F , Colomer D , Falini B , Montserrat E , Campo E. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B - cell lymphoma .", "label": "", "metadata": {}, "score": "65.1151"}
{"text": "Aberrations seen in GCB DLBCL included amplification of the mir-17 - 92 microRNA in the MIHG1 locus cluster on chromosome 13 , which has been shown to collaborate with MYC to transform B - cells and to reduce apoptotic activity [ 38 ] .", "label": "", "metadata": {}, "score": "65.12286"}
{"text": "In patients treated with a combination of rituximab and chemotherapy , the clinical significance of the GCB / ABC subtyping is more controversial [ 5 ] .", "label": "", "metadata": {}, "score": "65.158356"}
{"text": "Addition of ritux- imabtocurrent treatment resistance to chemotherapy in elderly individuals with DLBCL expressing bcl-2 , resulting in similar outcomes in both groups of patients with and without bcl-2 expres- sion ( 4 ) .", "label": "", "metadata": {}, "score": "65.21441"}
{"text": "The interaction between BMI and gender was also not statistically significant ( Table 3 ) .Discussion .To our knowledge , this is the largest study evaluating the impact of gender and BMI independently of aaIPI score and age in patients with DLBCL who were prospectively treated with R - CHOP in phase III trials .", "label": "", "metadata": {}, "score": "65.23312"}
{"text": "In this review , we explored associated copy number alterations ( CNA ) in 2008 WHO - defined DLBCL subtypes by array CGH .Certain chromosomal aberrations that were significantly more frequent in a particular DLBCL subtype than in the others , and some of these aberrations were associated with clinical outcome .", "label": "", "metadata": {}, "score": "65.23404"}
{"text": "In vitro addition of lenalidomide to PBMC of healthy individuals significantly increased their NK cell natural cytotoxicity ( Davies et al . , 2001 [ 34 ] ) in a CD4+T cell and IL-2 dependent manner [ 35 , 36 ] .", "label": "", "metadata": {}, "score": "65.27208"}
{"text": "View Article PubMed .Hongyo T : Frequent p53 mutations at dipyrimidine sites in patients with pyothorax - associated lymphoma .Cancer Res .PubMed .", "label": "", "metadata": {}, "score": "65.38168"}
{"text": "Interestingly , cases with PTEN deletion had a t(14;18 ) translocation suggesting that loss of PTEN may play a significant role in the pathogenesis of GCB DLBCL with t(14;18 ) .", "label": "", "metadata": {}, "score": "65.38547"}
{"text": "PubMed Central View Article PubMed .Colomo L : Diffuse large B - cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities .", "label": "", "metadata": {}, "score": "65.497345"}
{"text": "We will focus on these types of data ; 1 ) array based CGH ; 2 ) classical CGH ; and 3 ) gene expression profiling studies .", "label": "", "metadata": {}, "score": "65.529785"}
{"text": "Intravascular large B - cell lymphoma .Intravascular Large B - cell lymphoma ( ILBCL ) is differentiated by localization of atypical lymphomatous cells within smaller vessels and capillaries [ 1 , 71 ] .", "label": "", "metadata": {}, "score": "65.59278"}
{"text": "Differing provisions from the publisher 's actual policy or licence agreement may be applicable . \"Furthermore , most patients with low SUVmax or categorized into the very good prognostic group by R - IPI sustained CR only with R - CHOP or R - THPCOP therapy .", "label": "", "metadata": {}, "score": "65.59773"}
{"text": "B. Coiffier , E. Lepage , J. Bri\u00e8re et al . , \" Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large - B - cell lymphoma , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "65.76731"}
{"text": "10.1182/blood-2005 - 04 - 1399 .PubMed Central View Article PubMed .Chen W : Array comparative genomic hybridization reveals genomic copy number changes associated with outcome in diffuse large B - cell lymphomas .", "label": "", "metadata": {}, "score": "65.78618"}
{"text": "Histopathology .10.1046/j.1365 - 2559.2001.01197.x .View Article PubMed .Nishiu M : Distinct pattern of gene expression in pyothorax - associated lymphoma ( PAL ) , a lymphoma developing in long - standing inflammation .", "label": "", "metadata": {}, "score": "65.86659"}
{"text": "Higher Ki-67 was predictive of poor outcome in advanced stage mantle cell lymphoma treated with anti- CD20 immunochemotherapy , and an inverse correlation was observed between Ki-67 expression and response to immunochemotherapy containing rituximab in follicular lymphomas ( 20 , 21 ) .", "label": "", "metadata": {}, "score": "65.949715"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Pfreundschuh , L. Tr\u00fcmper , A. \u00d6sterborg et al . , \" CHOP - like chemotherapy plus rituximab versus CHOP - like chemotherapy alone in young patients with good - prognosis diffuse large - B - cell lymphoma : a randomised controlled trial by the MabThera International Trial ( MInT ) Group , \" The Lancet Oncology , vol .", "label": "", "metadata": {}, "score": "65.97192"}
{"text": "For gain / amplification of 19q , the overexpression of the SPIB gene seems to play a more functional role in the pathogenesis of ABC DLBCL .", "label": "", "metadata": {}, "score": "65.98552"}
{"text": "Liu YY , Leboeuf C , Shi JY , et al .Rituximab plus CHOP ( R - CHOP ) overcomes PRDM1-associated resistance to chemotherapy in patients with diffuse large B - cell lym- phoma .", "label": "", "metadata": {}, "score": "66.18541"}
{"text": "The clinical features of patients classified into the two Ki-67 expression groups , based on the cut- off value of 85 % , are summarized in Table 2 .", "label": "", "metadata": {}, "score": "66.19376"}
{"text": "Survival in GCB or Non - GCB Patients Treated with CHOP or R - CHOP .To study the impact of rituximab on the predictive value of subclassification on the basis of the cell of origin , we examined the survival outcomes according to treatment in the GCB or non - GCB subgroups , as defined by IHC stains .", "label": "", "metadata": {}, "score": "66.24831"}
{"text": "Host immune gene polymorphisms including TNF \u03b1 and IL10 predict late survival in DLBCL patients in the prerituximab era [ 23 ] .In accordance , the combined elevation of both TNF \u03b1 and IL-10 in sera of DLBCL patients at diagnosis has been shown to negatively impact on prognosis [ 24 ] .", "label": "", "metadata": {}, "score": "66.25459"}
{"text": "14 , pp .3276 - 3284 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. E. Calle , C. Rodriguez , K. Walker - Thurmond , and M. J. Thun , \" Overweight , obesity , and mortality from cancer in a prospectively studied cohort of U.S. Adults , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "66.34813"}
{"text": "Muris JJ : Apoptosis resistance and response to chemotherapy in primary nodal diffuse large B - cell lymphoma .Hematol Oncol .10.1002/hon.774 .", "label": "", "metadata": {}, "score": "66.40152"}
{"text": "Toxicity of Lenalidomide Alone in DLBCL .The neutropenia was rarely complicated with a febrile neutropenia , reported in 2 - 6 % of the patients .", "label": "", "metadata": {}, "score": "66.52392"}
{"text": "4 , pp .477 - 481 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. S. Nowakowski , B. LaPlant , T. M. Habermann et al . , \" Lenalidomide can be safely combined with R - CHOP ( R2CHOP ) in the initial chemotherapy for aggressive B - cell lymphomas : phase I study , \" Leukemia , vol .", "label": "", "metadata": {}, "score": "66.544334"}
{"text": "4 , pp .477 - 481 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. S. Nowakowski , B. LaPlant , T. M. Habermann et al . , \" Lenalidomide can be safely combined with R - CHOP ( R2CHOP ) in the initial chemotherapy for aggressive B - cell lymphomas : phase I study , \" Leukemia , vol .", "label": "", "metadata": {}, "score": "66.544334"}
{"text": "Median PFS was 5.4 months .Among 23 patents with transformed follicular lymphoma , ORR was 57 % , with 26 % of CR ; among 7 patients with transformed chronic lymphocytic leukemia / small lymphocytic lymphoma , ORR was 0 and none reached CR .", "label": "", "metadata": {}, "score": "66.59646"}
{"text": "Blood .10.1182/blood-2007 - 09 - 111948 .PubMed Central View Article PubMed .Niu H , Ye BH , Dalla - Favera R : Antigen receptor signaling induces MAP kinase - mediated phosphorylation and degradation of the BCL-6 transcription factor .", "label": "", "metadata": {}, "score": "66.6429"}
{"text": "PubMed Central View Article PubMed .Morgensztern D , Govindan R : Is there a role for cetuximab in non small cell lung cancer ?Clin Cancer Res .", "label": "", "metadata": {}, "score": "66.74002"}
{"text": "10.1084/jem.194.12.1861 .PubMed Central View Article PubMed .Lam LT : Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B - cell lymphoma defined by gene expression profiling .", "label": "", "metadata": {}, "score": "66.76953"}
{"text": "One hundred and eight patients with diffuse large B - cell lymphoma were included .As the previous study , the treatment consisted in lenalidomide 25 mg orally once daily on days 1 - 21 of every 28 day cycle .", "label": "", "metadata": {}, "score": "66.94979"}
{"text": "11 , pp .3909 - 3918 , 1997 .View at Google Scholar \u00b7 View at Scopus .B. Coiffier , E. Lepage , J. Bri\u00e8re et al . , \" Chop chemotherapy plus rituximab compared with chop alone in elderly patients with diffuse large - B - cell lymphoma , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "66.99324"}
{"text": "[ Show abstract ] [ Hide abstract ] ABSTRACT : Successful cancer management depends on accurate diagnostics along with specific treatment protocols .Current diagnostic techniques need to be improved to provide earlier detection capabilities , and traditional chemotherapy approaches to cancer treatment are limited by lack of specificity and systemic toxicity .", "label": "", "metadata": {}, "score": "67.021774"}
{"text": "2040 - 2045 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Pfreundschuh , J. Schubert , M. Ziepert et al . , \" Six versus eight cycles of bi - weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20 + B - cell lymphomas : a randomised controlled trial ( RICOVER-60 ) , \" The Lancet Oncology , vol .", "label": "", "metadata": {}, "score": "67.05567"}
{"text": "We analyzed Ki-67 expression and its correlation with prognosis in 144 patients with DLBCL treated with rituximab plus CHOP ( R - CHOP ) between July 2003 and January 2008 .", "label": "", "metadata": {}, "score": "67.13015"}
{"text": "The same schedule of lenalidomide was tested by Witzig in the NHL-003 international phase II trial for relapsed or refractory aggressive B - cell non - Hodgkin 's lymphoma .", "label": "", "metadata": {}, "score": "67.24424"}
{"text": "Ivanov described a case report of a 65-year - old DLBCL patient relapsed after four lines of chemotherapy that included high - dose chemotherapy plus autologous stem cell transplantation .", "label": "", "metadata": {}, "score": "67.24807"}
{"text": "We studied 204 patients with de novo DLBCL ( 107 treated with first - line CHOP ; 97 treated with first - line R - CHOP ) , patients being stratified into GCB and non - GCB on the basis of BCL-6 , CD10 , and MUM1 protein expression .", "label": "", "metadata": {}, "score": "67.275085"}
{"text": "Feys T : A detailed inventory of DNA copy number alterations in four commonly used Hodgkin 's lymphoma cell lines .Haematologica .10.3324/haematol.11073 .", "label": "", "metadata": {}, "score": "67.44617"}
{"text": "However , the impact of BMI on outcomes in NHL is not clear , as demonstrated by the controversial results in the literature .Indeed , a recent retrospective analysis in 2534 male United States veterans demonstrated that being overweight or obese was associated with a prolonged OS , even in the rituximab era [ 46 ] .", "label": "", "metadata": {}, "score": "67.46519"}
{"text": "Detailed Description .Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 2 .Study Design ICMJE .Endpoint Classification : Safety / Efficacy Study Intervention Model : Single Group Assignment Masking : Open Label Primary Purpose : Treatment .", "label": "", "metadata": {}, "score": "67.49935"}
{"text": "An alternative microarray technology that has been extensively used in the classification of DLBCL is gene expression profiling .Studies using gene expression profiling have stratified DLBCL into favorable and unfavorable groups i.e. , the germinal center B - cell like ( GCB ) and the activated B - cell like ( ABC ) DLBCL respectively [ 1 , 10 ] .", "label": "", "metadata": {}, "score": "67.531715"}
{"text": "ILBCL is known as the great imitator due to the fact that it presents with a broad spectrum of nonspecific symptoms with no distinct array CGH profile [ 10 ] .", "label": "", "metadata": {}, "score": "67.53929"}
{"text": "1414 - 1418 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. K. Khamly , V. J. Thursfield , M. Fay et al . , \" Gender - specific activity of chemotherapy correlates with outcomes in chemosensitive cancers of young adulthood , \" International Journal of Cancer , vol .", "label": "", "metadata": {}, "score": "67.69728"}
{"text": "This discrepancy is most likely due to the increasing difference in the incidence of lymphoma between genders .Indeed , the LNH03 - 6B and LNH03 - 2B studies were conducted during the same period of time ( 2003 - 2008 ) and after the LNH98 - 5 study ( 1998 - 2000 ) .", "label": "", "metadata": {}, "score": "67.70846"}
{"text": "Grogan TM , Lippman SM , Spier CM , Slymen DJ , Rybski JA , Rangel CS , Richter LC , Miller TP .Independent prog- nostic significance of a nuclear proliferation antigen in dif- fuse large cell lymphomas as determined by the monoclonal antibody Ki-67 .", "label": "", "metadata": {}, "score": "67.71037"}
{"text": "J Clin Oncol 2005 ; 23:5027 - 33 .Coiffier B , Lepage E , Briere J , et al .CHOP Chemother- apy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large - B - Cell Lymphoma .", "label": "", "metadata": {}, "score": "67.77942"}
{"text": "Sehn LH , Berry B , Chhanabhai M , et al .The revised International Prognostic Index ( R - IPI ) is a better predic- tor of outcome than the standard IPI for patients with dif- fuse large B - cell lymphoma treated with R - CHOP .", "label": "", "metadata": {}, "score": "67.82381"}
{"text": "Heyning FH : Array - based comparative genomic hybridisation analysis reveals recurrent chromosomal alterations in primary diffuse large B cell lymphoma of bone .J Clin Pathol .", "label": "", "metadata": {}, "score": "67.8333"}
{"text": "McClure RF : Adult B - cell lymphomas with burkitt - like morphology are phenotypically and genotypically heterogeneous with aggressive clinical behavior .Am J Surg Pathol .", "label": "", "metadata": {}, "score": "67.89834"}
{"text": "Lossos IS , Morgensztern D. Prognostic biomarkers in diffuse large B - cell lymphoma .J Clin Oncol 2006;24:995- 1007 .Szczuraszek K , Mazur G , Jelen M , Dziegiel P , Surowiak P , Zabel M. Prognostic significance of Ki-67 antigen expression in non - Hodgkin 's lymphomas .", "label": "", "metadata": {}, "score": "68.04974"}
{"text": "( HealthDay)-Guidelines , issued jointly by the American Society of Clinical Oncology ( ASCO ) and Cancer Care Ontario ( CCO ) in Canada , highlight recent advances in treating hormone - therapy - resistant advanced prostate cancer .", "label": "", "metadata": {}, "score": "68.05734"}
{"text": "18 , pp .2240 - 2247 , 2012 .View at Publisher \u00b7 View at Google Scholar .G. Svensson , S.-B. Ewers , O. Ohlsson , and H. Olsson , \" Prognostic factors in lung cancer in a defined geographical area over two decades with a special emphasis on gender , \" The Clinical Respiratory Journal , vol .", "label": "", "metadata": {}, "score": "68.14628"}
{"text": "10.1111/j.1365 - 2141.2006.06114.x .View Article PubMed .Kreisel F : High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B - cell lymphoma that predict response to immuno - chemotherapy .", "label": "", "metadata": {}, "score": "68.19975"}
{"text": "Saito B , Shiozawa E , Yamochi - Onizuka T , Adachi D , Nakamaki T , Tomoyasu S , Omine M , Mitsuya T , Takim- oto M , Ota H. Efficacy of rituximab plus chemotherapy in follicular lymphoma depends on Ki-67 expression .", "label": "", "metadata": {}, "score": "68.29958"}
{"text": "Seven courses were administered , obtaining CR ; patient was in remission at 20 months after the end of treatment [ 15 ] .Lenalidomide as single agent was also tested on transformed lymphoma , such as transformed follicular lymphoma and transformed chronic lymphocytic leukemia / small lymphocytic lymphoma .", "label": "", "metadata": {}, "score": "68.34729"}
{"text": "Large B - cell lymphoma arising in HHV8 + multicentric castleman disease .LBCL occurring in HHV8 + associated multicentric castleman disease is characterized by monoclonal proliferation of HHV8 + lymphoid cells in the presence of multicentric castleman disease [ 1 ] .", "label": "", "metadata": {}, "score": "68.41292"}
{"text": "Farinha P , Sehn L , Skinnider B , Wu L , Patten N , Truong S , Connors JM , Gascoyne RD .Strong p53 expression is an independent predictor of outcome in de novo diffuse large B cell lymphoma ( DLBCL ) treated with either CHOP or CHOP - R. ASH Annual Meeting Abstracts 2006;108:812 .", "label": "", "metadata": {}, "score": "68.52164"}
{"text": "Coiffier B , Lepage E , Briere J , et al .CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large - B - cell lymphoma .", "label": "", "metadata": {}, "score": "68.70269"}
{"text": "Approximately 35 - 50 % of INT cases have MYC rearrangements [ 69 , 70 ] with a concurrent BCL-2 translocation ( \" double - hit lymphoma \" ) in approximately 15 % of cases .", "label": "", "metadata": {}, "score": "68.70285"}
{"text": "24 , pp .5667 - 5675 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. H. Sehn , B. Berry , M. Chhanabhai et al . , \" The revised international prognostic Index ( R - IPI ) is a better predictor of outcome than the standard IPI for patients with diffuse large B - cell lymphoma treated with R - CHOP , \" Blood , vol .", "label": "", "metadata": {}, "score": "68.736786"}
{"text": "16 , pp .2717 - 2724 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. R\u00e9cher , B. Coiffier , C. Haioun et al . , \" Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B - cell lymphoma ( LNH03 - 2B ) : an open - label randomised phase 3 trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "68.803"}
{"text": "Primary effusion lymphoma .Primary Effusion Lymphoma ( PEL ) is another rare subtype of DLBCL that presents as an extravascular collection of fluids with no identifiable tumor mass .", "label": "", "metadata": {}, "score": "68.8479"}
{"text": "Median PFS for all 217 patients was 3.7 months ; for 77 responders , the median response duration lasted 10.6 months .Despite the fact that patients were heavily pretreated , lenalidomide was well tolerated .", "label": "", "metadata": {}, "score": "68.91002"}
{"text": "In 2006 , Hummel et al .[69 ] using aCGH reported most of these cases with a high chromosomal complexity with a score of 6 or more abnormalities with a MYC rearrangement .", "label": "", "metadata": {}, "score": "68.98543"}
{"text": "No significant difference in survival was observed between patients with GCB and non - GCB DLBCL ( 27 ) .PRDM1b gene expression was associated with poor prognosis in non - GCB DLBCL patients treated with CHOP but not R - CHOP ( 6 ) .", "label": "", "metadata": {}, "score": "69.0429"}
{"text": "Differences were observed in responses rates , PFS and OS .ORR rate was significantly higher in patients with non - GCB - like DLBCL compared to patients with GCB - like DLBCL ( OOR rates , 53 % versus 9 % , . )", "label": "", "metadata": {}, "score": "69.04591"}
{"text": "Complete remission is frequently obtained with a combination of chemotherapy and radiotherapy [ 9 , 46 ] .In 2010 , Heyning et al .[", "label": "", "metadata": {}, "score": "69.06283"}
{"text": "6 , pp .473 - 476 , 1995 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. Salles , J. F. Seymour , F. Offner , et al . , \" Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy ( PRIMA ) : a phase 3 , randomised controlled trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "69.06922"}
{"text": "The majority of studies on LG have failed to identify unique chromosomal aberrations ; however , a study by Godde - Salz et al .[ 77 ] reported few consistent chromosome aberrations including trisomy of chromosome 3 and 5 along with duplications of the X chromosome .", "label": "", "metadata": {}, "score": "69.18547"}
{"text": "1136 - 1143 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. R\u00e9cher , B. Coiffier , C. Haioun et al . , \" Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B - cell lymphoma ( LNH03 - 2B ) : an open - label randomised phase 3 trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "69.21706"}
{"text": "AlShemmari SH , Ameen RM , Sajnani KP .Extranodal lymphoma : a comparative study .Hematology 2008;13:163 - 9 .Yamauchi A , Fujita S , Ikeda J , et al .", "label": "", "metadata": {}, "score": "69.40848"}
{"text": "Ongoing trials should clarify the feasibility of lenalidomide in association with other drugs , such as with platinum containing regimens ( oxaliplatinum - cytarabine or carboplatinum - idarubicine - etoposide ) or with mTOR inhibitors ( everolimus and temsirolimus ) or with bendamustine or with monoclonal antibodies ( GA-101 ) .", "label": "", "metadata": {}, "score": "69.47995"}
{"text": "Although the mechanism of action of rituximab remains to be fully elucidated , complement - dependent and antibody - dependent cellular cytotoxic effects on CD20-positive malignant B cells have been suggested ( 30 ) , which may be affected by the degree of CD20 expression rather than the proliferation index .", "label": "", "metadata": {}, "score": "69.51318"}
{"text": "Although the adoption of R - CHOP ( rituximab in combination with CHOP ) as the new standard of care has led to improved outcomes for DLBCL , patients who fail in first - line therapy remain a difficult challenge .", "label": "", "metadata": {}, "score": "69.57733"}
{"text": "The introduction of rituximab to the DLBCL treatment regime has led to alterations in the significance of previous prognostic factors .Methods : We analyzed Ki-67 expression and its correlation with prognosis in 144 patients with DLBCL treated with rituximab plus CHOP ( R - CHOP ) between July 2003 and January 2008 .", "label": "", "metadata": {}, "score": "69.62647"}
{"text": "In One study [ 50 ] , using array CGH and fluorescent in - situ hybridization on 6 well characterized cases of PCBCL reported distinct genomic aberrations .", "label": "", "metadata": {}, "score": "69.69188"}
{"text": "Another distinctive feature of ABC DLBCL compared to the other two molecular subtypes was deletion of the INK4a / ARF tumor suppressor locus ; 30 % of the ABC DLBCL cases were deleted compared to 4 % in GCB DLBCL and 6 % in PMBL .", "label": "", "metadata": {}, "score": "69.789276"}
{"text": "We compared patient outcomes between the CHOP group and the R - CHOP group .A significant difference in outcome was observed between the two groups .", "label": "", "metadata": {}, "score": "69.82419"}
{"text": "329 , no .14 , pp .987 - 994 , 1993 .Q. Li , E. T. Chang , B. A. Bassig , et al . , \" Body size and risk of Hodgkin 's lymphoma by age and gender : a population - based case - control study in Connecticut and Massachusetts , \" Cancer Causes & Control , vol .", "label": "", "metadata": {}, "score": "69.87535"}
{"text": "Twenty - three elderly DLCL patients at median age 74.2 years , heavily pretreated with a median of three prior therapies ( range , 2 to 8) , were enrolled and treated with rituximab plus lenalidomide .", "label": "", "metadata": {}, "score": "69.98758"}
{"text": "PubMed .Luan SL : Primary effusion lymphoma : genomic profiling revealed amplification of SELPLG and CORO1C encoding for proteins important for cell migration .J Pathol .", "label": "", "metadata": {}, "score": "70.04312"}
{"text": "Review of the literature .Diffuse large B - cell lymphoma , not otherwise specified ( NOS ) .DLBCL NOS consists of all DLBCL cases that do not fit into one of the other specific subtypes or disease entities [ 1 ] .", "label": "", "metadata": {}, "score": "70.11336"}
{"text": "Grade III - IV neutropenia occurred in 28 % to 88 % of the patients , and Grade III - IV thrombocytopenia in 10 to 30 % of the patients .", "label": "", "metadata": {}, "score": "70.12793"}
{"text": "In another study by Tagawa et al .[ 22 ] , array CGH was used to further study the aberrations associated with ABC DLBCL and GBC DLBCL .", "label": "", "metadata": {}, "score": "70.29574"}
{"text": "Deep vein thrombosis was described in 2 % of the patients .These toxicities required a dose reduction in one third of the patients in both trials [ 52 , 53 ] ( Table 2 ) .", "label": "", "metadata": {}, "score": "70.40223"}
{"text": "In the landscape of novel drugs , immunomodulating drugs ( IMiDs ) represent now a real opportunity to ameliorate prognosis in DLBCL .Lenalidomide : Mechanism of Action and Rationale .", "label": "", "metadata": {}, "score": "70.53053"}
{"text": "June 2016 ( final data collection date for primary outcome measure ) .Eligibility Criteria ICMJE .Inclusion Criteria : .More than 2 cm sized lesion in conventional CT scan , .", "label": "", "metadata": {}, "score": "70.70341"}
{"text": "20798 - 20803 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. Yeung , P. Janosch , B. McFerran et al . , \" Mechanism of suppression of the Raf / MEK / extracellular signal - regulated kinase pathway by the Raf kinase inhibitor protein , \" Molecular and Cellular Biology , vol .", "label": "", "metadata": {}, "score": "70.76567"}
{"text": "Although carefully collected , accuracy can not be guaranteed .The impact factor represents a rough estimation of the journal 's impact factor and does not reflect the actual current impact factor .", "label": "", "metadata": {}, "score": "70.84376"}
{"text": "There were no differences between the 3 trials with respect to the BMI subgroups , with similar median BMI values of 24.5 , 24.3 and 25 kg / m 2 for the LNH 98 - 5 , 03 - 2B , and 03 - 6B studies , respectively .", "label": "", "metadata": {}, "score": "70.85269"}
{"text": "This work was supported by the Medical Science Foundation of Guangdong Province ( B2009087 ) and the Guangdong Natural Science Foundation ( S2011040004296 ) .References .", "label": "", "metadata": {}, "score": "70.90059"}
{"text": "Progression - free survival ( PFS ) was defined as the time from inclusion until disease progression / relapse or death from any cause ; overall survival ( OS ) was defined as the time from inclusion to death from any cause .", "label": "", "metadata": {}, "score": "70.90362"}
{"text": "Among patients with tFL , ORR was 57 % , with a median response duration of 12.8 months .None of the patients with tCLL / SLL responded to lenalidomide monotherapy .", "label": "", "metadata": {}, "score": "70.93515"}
{"text": "These studies will assess the effectiveness of R - CHOP in combination with bortezomib and antisense BCL-2 antibody in previously untreated non - GCB DLBCL patients .", "label": "", "metadata": {}, "score": "71.05156"}
{"text": "PubMed .Alizadeh AA : Distinct types of diffuse large B - cell lymphoma identified by gene expression profiling .Nature .View Article PubMed .", "label": "", "metadata": {}, "score": "71.057724"}
{"text": "54 , no . 7 , pp .1435 - 1438 , 1984 .View at Google Scholar \u00b7 View at Scopus .S. H. Swerdlow , E. Campo , N. L. Harris , et al . , WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , IARC Press , Lyon , France , 2008 .", "label": "", "metadata": {}, "score": "71.10912"}
{"text": "Results .Patient Characteristics .Of the 204 patients , 107 were treated initially with the standard CHOP regimen and 97 were treated with R - CHOP .", "label": "", "metadata": {}, "score": "71.23782"}
{"text": "Full - text . Intro-ductionoftheanti - CD20 DLBCLtherapy in recent improved survival ( 1 , 2 ) and altered the predictive values of known prognostic factors in DLBCL ( 3 - 6 ) .", "label": "", "metadata": {}, "score": "71.43617"}
{"text": ", although the difference was not statistically significant , likely as a result of the low number of patients .However , in this subgroup , the PFS survival curves were comparable ; the median PFS was 68 months for men and indeterminate for women ( . , as shown by the survival curves , although the difference was not significant , most likely due to the low number of patients .", "label": "", "metadata": {}, "score": "71.4688"}
{"text": "In all histologic subgroups , ORR was 35 % with CR 13 % , partial remission ( PR ) 22 % , and stable disease 21 % ; ORR for DLBCL was 28 % .", "label": "", "metadata": {}, "score": "71.52617"}
{"text": "The extent of disease had been determined at first presentation by physical examination , serum lactate dehydrogenase concentration , full blood count , and computed tomography of the chest and abdomen .", "label": "", "metadata": {}, "score": "71.72475"}
{"text": "Lymphomatoid granulomatosis .Lymphomatoid Granulomatosis ( LG ) is an angiocentric and angiodestructive proliferative B - cell neoplasm that involves extra - nodal sites .LG is composed of malignant B - cells that are Epstein - Barr virus - positive combined with reactive T - cells .", "label": "", "metadata": {}, "score": "71.74231"}
{"text": "150 \u00aa 2010 John Wiley & Sons A / S .Page 3 . follow - up date for surviving patients .Event - free survival ( EFS ) was assessed from the first day of chemotherapy until relapse , disease progression , and death from any cause or last follow - up .", "label": "", "metadata": {}, "score": "71.83448"}
{"text": "10.1084/jem.20062041 .PubMed Central View Article PubMed .O'Donnell KA : c - Myc - regulated microRNAs modulate E2F1 expression .Nature .10.1038/nature03677 .", "label": "", "metadata": {}, "score": "71.8693"}
{"text": "The LNH03 - 6B trial [ 21 ] included 602 patients randomised to R - CHOP treatment every 2 or 3 weeks ( Figure 1 ) .", "label": "", "metadata": {}, "score": "71.95944"}
{"text": "To assess the impact of BMI and gender on OS and PFS independently of the aaIPI score , we pooled 985 patients that were prospectively included in GELA studies and uniformly treated with R - CHOP .", "label": "", "metadata": {}, "score": "71.98364"}
{"text": "Palanisamy N : Similar patterns of genomic alterations characterize primary mediastinal large - B - cell lymphoma and diffuse large - B - cell lymphoma .", "label": "", "metadata": {}, "score": "72.05163"}
{"text": "It was detected in 9 % of the cases , while never identified in GCB DLBCL or PMBL .NFKBIZ activates targets in the nuclear factor kB pathway a hallmark for ABC DLBCL [ 36 ] .", "label": "", "metadata": {}, "score": "72.05409"}
{"text": "Moreover , lenalidomide inhibit the suppressor function of the T REG cells against autologous responder cells in vitro .This inhibitory activity is associated with reduction of FOXP3 and OX40 expression .", "label": "", "metadata": {}, "score": "72.09915"}
{"text": "The number of tumour - infiltrating TIA-1 + cytotoxic T cells but not FOXP3 + regulatory T cells predicts outcome in diffuse large B - cell lymphoma .", "label": "", "metadata": {}, "score": "72.101295"}
{"text": "Finally , if females always exhibited a longer PFS and OS than males , the difference in PFS and OS observed between males and females was most significant in the elderly population .", "label": "", "metadata": {}, "score": "72.5842"}
{"text": "The aim of the analysis was to study the impact of gender and BMI independently from the IPI score .Those factors were therefore selected on the basis of clinical relevance for multivariate analysis .", "label": "", "metadata": {}, "score": "72.59947"}
{"text": "Germinal center and nongerminal center B - cell subgroups were similar in terms of stage , international prognostic index score , prior number of treatments , and rituximab resistance .", "label": "", "metadata": {}, "score": "72.73122"}
{"text": "identified 3q23 - 3q28 ( 31 % ) , 6q22.31-q24.1 ( 44 % ) and 9p21.3 ( 50 % ) in high frequency for CD5 + DLBCL .", "label": "", "metadata": {}, "score": "73.27612"}
{"text": "Keywords .DLBCL Array CGH Genomic profiles .Electronic supplementary material .The online version of this article ( doi : 10 .1186/\u200b1756 - 8722 - 5 - 54 ) contains supplementary material , which is available to authorized users .", "label": "", "metadata": {}, "score": "73.27646"}
{"text": "Patients and Methods .Patients .To present homogenous data , the current study only included patients treated with R - CHOP in these different randomised studies .", "label": "", "metadata": {}, "score": "73.33747"}
{"text": "Response criteria Responses to chemotherapy were assessed according to the Cheson 's criteria ( 26 ) .Routine follow - up imaging analyses were performed every 3 months for the first 2 yr , every 6 months for the next 3 yr and yearly there- after or whenever clinically indicated .", "label": "", "metadata": {}, "score": "73.370895"}
{"text": "Patients ' initial clinical characteristics as reported by the different trials .( b )Patients ' initial BMI , gender , and aaIPI scores according to the different trials .", "label": "", "metadata": {}, "score": "73.38811"}
{"text": "In the phase I , three patients received 15 mg , 3 patients 20 mg , and 18 patients 25 mg of lenalidomide ; no DLT was found and 25 mg days 1 - 10 was the recommended dose for phase II .", "label": "", "metadata": {}, "score": "73.39993"}
{"text": "Classical CGH studies by Franke et al .[52 ] revealed most common gains of 4q13q38,18q21 , Xq and Xp21-p11 , as well as recurrent losses 17p .", "label": "", "metadata": {}, "score": "73.46935"}
{"text": "The complexes formed were visualized with diaminobenzidine chromogen substrate .Ki-67-positive cells were evaluated among 1000 tumor cells by nuclear staining and counted under high magnification ( X 400 ) in the highest labeling area .", "label": "", "metadata": {}, "score": "73.534134"}
{"text": "Pfreundschuh M , Trumper L , Kloess M , et al .Two - weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good - prognosis ( normal LDH ) aggressive lymphomas : results of the NHL - B1 trial of the DSHNHL .", "label": "", "metadata": {}, "score": "73.555145"}
{"text": "In total , 38 % of ABC DLBCL had an increase in FOXP1 CNA compared to 4 % and 3 % for GCB DLBCL and PMBL each .", "label": "", "metadata": {}, "score": "73.66632"}
{"text": "Pfreundschuh M , Trumper L , Kloess M , et al .Two - weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas : results of the NHL - B2 trial of the DSHNHL .", "label": "", "metadata": {}, "score": "73.71172"}
{"text": "rituximab plusCHOP ( ECOG)performance Diagnosis Diagnosis was based on morphological and immunohis- tochemical examination of biopsy materials using routine techniques .Histopathological classification was based on the World Health Organization ( WHO ) criteria for DLBCL ( 22 ) .", "label": "", "metadata": {}, "score": "73.81589"}
{"text": "However , such a difference did not exist in patients treated with R - CHOP , which suggests that the expression of germinal center markers does not correlate with a more favorable outcome in the rituximab era .", "label": "", "metadata": {}, "score": "74.000244"}
{"text": "Patient and disease characteristics for both treatment cohorts , including the five clinical parameters that comprise the IPI , are listed in Table 1 .Otherwise , the clinical features were not significantly different between the rituximab and control groups .", "label": "", "metadata": {}, "score": "74.08518"}
{"text": "Ten patients were eligible for lenalidomide maintenance .At the end of the entire treatment regimen , CR was 35 % .At a median follow - up of 16 months , the estimated 1-year - disease - free - survival was 34.8 % and the 18-month OS rate for the whole study population was 55.1 % .", "label": "", "metadata": {}, "score": "74.17554"}
{"text": "10.1038/leu.2008.240 .PubMed Central View Article PubMed .Kumar V : Common variants on 14q32 and 13q12 are associated with DLBCL susceptibility .J Hum Genet .", "label": "", "metadata": {}, "score": "74.21185"}
{"text": "To improve these results , several changes to conventional R - CHOP have emerged either in shortening intervals between cycles [ 9 ] or giving alternative regimens with intensified doses of chemotherapy [ 10 ] .", "label": "", "metadata": {}, "score": "74.47722"}
{"text": "Based on the WHO classification scheme , there are three types of primary cutaneous B - cell Lymphoma : leg type ( PCBCL ) , follicular center , and marginal zone .", "label": "", "metadata": {}, "score": "74.51704"}
{"text": "Sverker Hasselblom Haematology and Coagulation Section , Department of Medicine , Sahlgrenska University Hospital , Goteborg , Sweden Acta Oncol 43:758 - 65 .A high intratumoural microvessel density was correlated with a high degree of Ki-67 positive tumour cells and an inferior overall survival ... .", "label": "", "metadata": {}, "score": "74.53732"}
{"text": "Using classical CGH analysis , Yamato et al .[ 60 ] showed the amplification of the 8q24 band region in 7 PAL cases .Amplification was later confirmed in four cases by southern blot analysis .", "label": "", "metadata": {}, "score": "74.59495"}
{"text": "Department of Pathology , The UT Southwestern Medical Center .Clinical Cytogenetics , The University of Texas Health Science Center at San Antonio .References .", "label": "", "metadata": {}, "score": "74.68019"}
{"text": "Yoon et al .Ki-67 in DLBCL treated with R - CHOP \u00aa 2010 John Wiley & Sons A / S 151 .Page 4 . expression group .", "label": "", "metadata": {}, "score": "74.80467"}
{"text": "However , a higher relapse rate among patients achieving CR after initial chemotherapy was observed in the high Ki-67 expression group .status .Thirty - two Survival analysis In total , 23 patients in the low Ki-67 group and 19 patients in the high Ki-67 group experienced relapse , progression , or death .", "label": "", "metadata": {}, "score": "74.81061"}
{"text": "Median age was 65 years , 53 % of patients had DLBCL , and all of them received at least four prior therapeutic regimens ; 92 % of patients had received prior rituximab and 29 % of them had been previously transplanted .", "label": "", "metadata": {}, "score": "74.879105"}
{"text": "Sverker Hasselblom Department of Internal Medicine , Sahlgrenska University Hospital , Gothenburg , Sweden Leuk Lymphoma 53:394 - 9 .In conclusion , moderately reduced R - CHOP is tolerable and effective for a considerable number of very elderly patients with DLBCL and high age by itself should not be a reason for excluding a patient with DLBCL from such treatment ... .", "label": "", "metadata": {}, "score": "75.02988"}
{"text": "Chromosome band region gains are provided on the right hand side of each chromosome , while genetic losses are shown on the left hand side of each chromosome ideogram .", "label": "", "metadata": {}, "score": "75.169785"}
{"text": "Finally , the CR , Cru , and PR rate at end of treatment were similar between the three studies ( shown in Table 2 ) .", "label": "", "metadata": {}, "score": "75.32393"}
{"text": "This drug has both antiproliferative and antiangiogenic activities .Lenalidomide 's activity is based on modulation of tumor - cell microenvironment and on stimulating the activity of effector cells , such as cytotoxic T and natural killer cells .", "label": "", "metadata": {}, "score": "75.55676"}
{"text": "Key words Ki-67 ; diffuse large B - cell lymphoma ; rituximab ; relapse ; prognosis Correspondence Cheolwon Suh , MD , Department of Oncology , Asan Medical Center , University of Ulsan College of Medicine , 86 Asanbyeongwon - gil , Songpa - gu , Seoul 138 - 736 , Korea .", "label": "", "metadata": {}, "score": "75.65729"}
{"text": "Grade 3 or 4 adverse events included neutropenia in 41 % , with only 2 % of febrile neutropenia , thrombocytopenia in 19 % , and anemia in 9.2 % .", "label": "", "metadata": {}, "score": "75.72911"}
{"text": "Anaplastic large cell lymphoma with expression of the anaplastic kinase protein is a rare neoplasm of ALK - positive monomorphic large B - cells with immunoblastic or plasmablastic morphology .", "label": "", "metadata": {}, "score": "75.83034"}
{"text": "No author has any financial disclosures related to this study .References 1 .Sehn LH , Donaldson J , Chhanabhai M , et al .", "label": "", "metadata": {}, "score": "75.87102"}
{"text": "Lenalidomide has been shown to inhibit the production of proinflammatory cytokines including TNF \u03b1 and to elevate the production of anti - inflammatory cytokine IL-10 from human PBMCs stimulated by LPS .", "label": "", "metadata": {}, "score": "75.91583"}
{"text": "Materials and Methods .Patient Selection and Tumor Specimens .We retrospectively studied 204 patients with de novo DLBCL diagnosed at Sun Yat - sen University Cancer Center between 1998 and 2005 .", "label": "", "metadata": {}, "score": "76.156425"}
{"text": "The overall response rate was 92.4 % .DLBCL relapsed in 16 patients after achieving CR .Median OS and EFS were not reached at a median follow - up period of 25.2 months ( range , 5.2 - 58.8 months ) .", "label": "", "metadata": {}, "score": "76.344215"}
{"text": "Sections of reactive tonsil and PAS were used as positive and negative controls , respectively .The proportion of positively stained tumor cells was estimated by two pathologists who had no knowledge of the corresponding clinical data .", "label": "", "metadata": {}, "score": "76.36272"}
{"text": "Initial Clinical Characteristics of the 985 Patients .The global population included 985 patients ( Figure 1 ) .The patients ' initial characteristics are described in Table 1 ( a ) .", "label": "", "metadata": {}, "score": "76.40585"}
{"text": "Am J Hematol 2007;82:893 - 7 .Chang KC , Huang GC , Jones D , Tsao CJ , Lee JY , Su IJ .Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal - center derived tumors .", "label": "", "metadata": {}, "score": "76.5052"}
{"text": "Patient navigation , or the linking of a newly diagnosed cancer patient with a professional trained in assisting patients though the complex journey of cancer diagnosis and treatment , may lead to better breast cancer care ... .", "label": "", "metadata": {}, "score": "76.58262"}
{"text": "Ki-67 in DLBCL treated with R - CHOP Yoon et al .152 \u00aa 2010 John Wiley & Sons A / S .Page 5 .", "label": "", "metadata": {}, "score": "76.63373"}
{"text": "Researchers have now been able , using high - resolution DNA technology , to develop ... .Journal of Clinical Oncology .The Journal of Clinical Oncology ( JCO ) is a medical journal published by the American Society of Clinical Oncology ( ASCO ) .", "label": "", "metadata": {}, "score": "76.66955"}
{"text": "10.1038/sj.leu.2403813 .View Article PubMed .Motoyama M : Positive and negative regulation of nuclear factor - kappaB - mediated transcription by IkappaB - zeta , an inducible nuclear protein .", "label": "", "metadata": {}, "score": "76.824165"}
{"text": "However , there were more patients with a low IPI score in the GCB subgroup ( 36.4 % versus 4.7 % ; . )Among the 97 patients treated with R - CHOP , there were 33 in the GCB subgroup and 64 in the non - GCB subgroup .", "label": "", "metadata": {}, "score": "76.836655"}
{"text": "Lenalidomide was initially introduced in the treatment of multiple myeloma and only in a second time was tested in lymphoma cell lines .In animal models of lymphoma , IMiDs and especially lenalidomide demonstrated a synergic action with rituximab ; the addition of lenalidomide to rituximab increased median survival in mice from 45 days to 58 days compared to rituximab alone [ 9 ] .", "label": "", "metadata": {}, "score": "76.89656"}
{"text": "Trisomy 3 was the most frequent aberration seen in ABC DLBCL ( 26 % ) .In cases with trisomy 3 , FOXP1 was the most frequently up - regulated gene .", "label": "", "metadata": {}, "score": "77.091064"}
{"text": "Colored insets show the main transcriptomic signatures described in DLBCL .Just outside the circle are the signatures with prognostic impact .Inside the circle are indicated the factors studied in DLBCL , either with bad ( red characters ) , good ( blue ) , or undetermined ( black ) prognostic impact .", "label": "", "metadata": {}, "score": "77.16912"}
{"text": "Ki-67 in DLBCL treated with R - CHOP Yoon et al .156 \u00aa 2010 John Wiley & Sons A / S .Page 9 .", "label": "", "metadata": {}, "score": "77.23401"}
{"text": "Nanomedicine approaches in cancer have great potential for clinically translatable advances that can positively impact the overall diagnostic and therapeutic process and result in enhanced quality of life for cancer patients .", "label": "", "metadata": {}, "score": "77.30004"}
{"text": "In efforts to better define PMBL , Palanisamy et al .[ 39 ] using classical CGH characterized PMBL by whole chromosome gains of 12 , 21 , 22 and whole chromosome loses of 11 , 13 , and 18 .", "label": "", "metadata": {}, "score": "77.357574"}
{"text": "In multivariate analyses , the following variables were included : BMI in groups , gender , age , interaction between BMI and gender , and aaIPI scores .", "label": "", "metadata": {}, "score": "77.37014"}
{"text": "Although male gender is commonly known as an independent poor prognostic factor in haematological malignancies [ 38 - 40 ] and also in solid tumors [ 41 - 43 ] , it does not yet influence therapeutic choices .", "label": "", "metadata": {}, "score": "77.38693"}
{"text": "ORR was 100 % with CR in 77 % of patients [ 17 ] .Lenalidomide dose was increased from 5 mg to 25 mg ( 5 mg per dose level ) , using a .", "label": "", "metadata": {}, "score": "77.39984"}
{"text": "Gender was a relevant prognostic factor for PFS and exhibited a strong trend for OS .Interestingly , the impact of gender on PFS and OS varied with BMI .", "label": "", "metadata": {}, "score": "77.5236"}
{"text": "Cancer 2002;94:2635 - 44 .Yoon et al .Ki-67 in DLBCL treated with R - CHOP \u00aa 2010 John Wiley & Sons A / S 157 .", "label": "", "metadata": {}, "score": "77.90453"}
{"text": "Nanomaterials can be used as MRI , optical imaging , and photoacoustic imaging contrast agents .When used as drug carriers , nanoformulations can increase tumor exposure to therapeutic agents and result in improved treatment effects by prolonging circulation times , protecting entrapped drugs from degradation , and enhancing tumor uptake through the enhanced permeability and retention effect as well as receptor - mediated endocytosis .", "label": "", "metadata": {}, "score": "77.93786"}
{"text": "Combination of lenalidomide and standard R - CHOP21 have been recently published or reported in meetings by several groups in phase I - II [ 56 ] .", "label": "", "metadata": {}, "score": "78.0348"}
{"text": "Variable results among study groups may result from diverse study populations , sample sizes , method of chosen Ki-67 threshold , and heterogeneous therapeutic regimens .", "label": "", "metadata": {}, "score": "78.52583"}
{"text": "Yoon et al .Ki-67 in DLBCL treated with R - CHOP \u00aa 2010 John Wiley & Sons A / S 155 .Page 8 .", "label": "", "metadata": {}, "score": "78.54874"}
{"text": "Ki-67 in DLBCL treated with R - CHOP Yoon et al .154 \u00aa 2010 John Wiley & Sons A / S .Page 7 .", "label": "", "metadata": {}, "score": "78.60516"}
{"text": "On the contrary , the RICOVER [ 3 , 16 ] study reported that , in patients with a lower body weight , the addition of rituximab to CHOP resulted in a significant improvement in PFS but not in patients with a higher body weight .", "label": "", "metadata": {}, "score": "78.92145"}
{"text": "One of the most frequent aberrations mentioned in this study was the loss of 9p21(83 % ) .Of the six patients with 9p21 deletion , all died in this study .", "label": "", "metadata": {}, "score": "79.0188"}
{"text": "The results of the univariate analysis for OS and PFS are presented in Table 3 . High aaIPI score , age older than 60 years , and male gender were associated with a shorter PFS ; the median PFS was 118 months for patients with low aaIPI scores versus 41 months for patients with high score ( .", "label": "", "metadata": {}, "score": "79.0712"}
{"text": "In multivariate analysis , gender was not anymore a relevant prognostic factor for PFS and OS ( even the difference was almost significant for OS , . ) , and aaIPI remained the strongest prognostic factor for both OS and PFS .", "label": "", "metadata": {}, "score": "79.22731"}
{"text": "One patient had pulmonary embolism of moderate severity and one patient has a deep vein thrombosis .Lenalidomide was stopped in five patients due to toxicity according to protocol defined criteria [ 18 ] .", "label": "", "metadata": {}, "score": "79.254616"}
{"text": "The follow - up period ranged from 6 to 167 months ( median , 53 months ) .For the R - CHOP group , 97 DLBCL patients aged 20 - 83 years ( median , 59.0 years ) were studied .", "label": "", "metadata": {}, "score": "79.50858"}
{"text": "Multivariate prog- nostic analyses were performed for OS and EFS using the Cox proportional hazards regression model .Statistical analysis was performed using the Statistical Package for Social Sciences ( spss ) Version 14.0 ( spss , Chicago , IL , USA ) .", "label": "", "metadata": {}, "score": "79.76703"}
{"text": "The 5-year OS for GCB and non - GCB patients treated with CHOP in our series was 65.0 % and 40.9 % , respectively ( . )", "label": "", "metadata": {}, "score": "80.14703"}
{"text": "It is an oral drug , easy to administer .The early antitumoral efficacy and immunomodulatory effect have been shown , and finally tolerance is acceptable .", "label": "", "metadata": {}, "score": "80.24039"}
{"text": "Forty patients were retrospectively analyzed using the Hans 's algorithm based on the expression of CD10 , BCL6 , and IRF4/MUM1 by immunohistochemistry [ 47 ] .", "label": "", "metadata": {}, "score": "80.30122"}
{"text": "It is published 3 times a month .The Journal 's impact factor in 2007 was 15.484 , making it one of the highest - impact journals in the field of oncology .", "label": "", "metadata": {}, "score": "80.34862"}
{"text": "A study carried out by Pasqualucci et al .[ 33 ] revealed aberrant somatic hypermutations targeting multiple genetic loci including PIMI , MYC , RHOH / TTF , and PAX .", "label": "", "metadata": {}, "score": "80.6117"}
{"text": "The P values for these analyses are based on the log - rank test .Cox proportional hazard multivariate analysis was performed to compare the prognostic importance of the different variables .", "label": "", "metadata": {}, "score": "81.1192"}
{"text": "IPI Was the Prognostic Fact for Both CHOP and R - CHOP Groups .We also explored the prognostic significance of the IPI .We used IPI scoring system , instead of individual included factors in IPI , and subgrouped the patient into low risk ( IPI score 0 and 1 ) and high risk ( IPI score more then 2 ) .", "label": "", "metadata": {}, "score": "81.282394"}
{"text": "Financial Disclosure : Dr. Barr is a Lymphoma Research Foundation Clinical Investigator and is supported in part by the Wilmot Research Foundation and the University of Rochester SPORE in Lymphoma grant ( CA-130805 - 02 ) .", "label": "", "metadata": {}, "score": "81.34887"}
{"text": "Germinal center B - cell ( GCB ) and non - GCB subtypes , which were originally characterized by gene expression studies [ 2 ] , have subsequently been validated at the protein level using IHC , as introduced by Hans et al .", "label": "", "metadata": {}, "score": "81.81235"}
{"text": "By cytogenetic analysis , one study reported complex karyotypes but no common abnormality was reported [ 62 ] .Plasmablastic lymphoma .Plasmablastic lymphoma ( PL ) is a scattered proliferation of large neoplastic cells that have the immunophenotype of plasma cells but resemble B - immunoblasts .", "label": "", "metadata": {}, "score": "82.27444"}
{"text": "The GCB and non - GCB groups were similar with regard to age and sex distribution .Among the 107 patients treated with CHOP , there were 44 in the GCB subgroup and 63 in the non - GCB subgroup ; this ratio being consistent with previous reports .", "label": "", "metadata": {}, "score": "82.401215"}
{"text": "A total of 202 of the 204 patients had all the necessary data available to calculate the IPI ; two of 204 patients had no record of serum lactate dehydrogenate concentration .", "label": "", "metadata": {}, "score": "82.86016"}
{"text": "The following treatment modalities were administered : 103 of 144 patients were subjected to R - CHOP chemotherapy for 6 - 8 courses with 3-wk intervals and 41 patients with stage I or local- ized stage II disease received R - CHOP chemotherapy , followed by involved field radiotherapy .", "label": "", "metadata": {}, "score": "82.97911"}
{"text": "Slides were pretreated in the microwave with citrate buffer ( pH 6.0 ) at 90 ?C for 10 min to retrieve antigen , immersed in 0.3 % hydrogen peroxide for 20 min to block endogenous peroxidase activity , washed , and incubated overnight at 4 ? C with normal bovine serum to reduce non - specific antibody binding .", "label": "", "metadata": {}, "score": "83.00132"}
{"text": "All interpretations of immunohistochemical stains were performed without knowledge of clinical outcome .Patients were staged according to the Ann Arbor staging classification system ( 24 ) .", "label": "", "metadata": {}, "score": "83.11586"}
{"text": "All patient data were collected prospectively and stored in a computerized database .Follow - up data were collected until October 31 , 2009 .The study protocol was approved by the institutional review board of the Asan Medical Center , Seoul , Korea .", "label": "", "metadata": {}, "score": "83.26334"}
{"text": "Among the patients who received CHOP , MUM1 expression was seen in 7/46 GCB cases and 41/63 non - GCB cases .There was a significant difference in the percentage of cases exhibiting MUM1 positivity between the GCB and non - GCB subgroups ( .", "label": "", "metadata": {}, "score": "83.32782"}
{"text": "Lenalidomide ( Revlimid , Celgene Corporation , Summit , NJ , USA ) , an analogue of thalidomide , is an immunomodulatory drug with pleiotropic mechanisms of action potentially adding to immunochemotherapy .", "label": "", "metadata": {}, "score": "83.46244"}
{"text": "Of the seven patients that died in this study , five cases had a deletion at 9p21 .This may suggests that loss of this region has important clinical significance .", "label": "", "metadata": {}, "score": "83.69423"}
{"text": "In a Cox regression analysis including gender , BMI , age , aaIPI score , and interaction between gender and BMI as variables , a high aaIPI score was the strongest factor independently associated with shorter OS and shorter PFS ( . )", "label": "", "metadata": {}, "score": "83.79576"}
{"text": "Large B - cell lymphoma of the bone ( LBCLB ) is a subtype of primary extra nodal DLBCL .It typically presents in the longer bones , such as the humerus , tibia , pelvis , spine or the femur .", "label": "", "metadata": {}, "score": "83.92935"}
{"text": "Action on NK Cells .Under normal circumstances of immune surveillance , human NK cells have inhibitory receptors that recognize MHC class I molecules as their cognate ligands on virtually every cell in the body [ 27 ] and activating receptors that sense stressed cells , that is , transformed or infected cells .", "label": "", "metadata": {}, "score": "84.07634"}
{"text": "Pyothorax - associated lymphoma .Pyothorax - associated Lymphoma ( PAL ) develops in the pleural cavity of patients with a history of long - standing pyothorax [ 1 ] .", "label": "", "metadata": {}, "score": "84.7827"}
{"text": "The lenalidomide dose levels tested were between 5 mg up to 25 mg / day .Duration of treatment by cycle was between 10 days to 14 days .", "label": "", "metadata": {}, "score": "84.994095"}
{"text": "Aberrations that were frequently seen included loss of 1p35 - 36.3 , 6q14 - 27 , 14q32 , 15q11 - 26 , trisomy 7 , gain of 1q21 - 44 , 6p21 and amplification of 2p16.1 .", "label": "", "metadata": {}, "score": "85.41701"}
{"text": "Authors ' Contribution . Y. Huang , S. Ye , and Y. Cao contributed equally to this study .Conflict of Interests .The authors indicated that no actual or potential conflict of interests exists .", "label": "", "metadata": {}, "score": "85.50791"}
{"text": "Lenalidomide in Diffuse Large B - Cell Lymphomas .Hematology 2 , San Giovanni Battista Hospital and University , c.so Bramante 88 , 10126 Torino , Italy .", "label": "", "metadata": {}, "score": "86.087944"}
{"text": "Ohno H : Epstein - Barr virus - positive diffuse large B - cell lymphoma carrying a t(9;14)(p13;q32 ) translocation .Int J Hematol .View Article .", "label": "", "metadata": {}, "score": "86.40968"}
{"text": "Lenalidomide in Diffuse Large B - Cell Lymphoma .Received 1 March 2012 ; Accepted 22 August 2012 .Academic Editor : Umberto Vitolo .Copyright \u00a9 2012 Catherine Thieblemont et al .", "label": "", "metadata": {}, "score": "86.70032"}
{"text": "Intervention : Drug : 131I - rituximab .Not Provided .Recruitment Status ICMJE .Recruiting .Estimated Enrollment ICMJE .Estimated Completion Date .June 2017 .", "label": "", "metadata": {}, "score": "89.455925"}
{"text": "Below are the links to the authors ' original submitted files for images .Competing interests .The authors declare that they have no competing interests .", "label": "", "metadata": {}, "score": "89.8472"}
{"text": "Peter Apelgren Section of Haematology and Coagulation , Department of Internal Medicine , Sahlgrenska University Hospital , Goteborg , Sweden Leuk Lymphoma 47:2505 - 16 .", "label": "", "metadata": {}, "score": "90.02697"}
{"text": "Here , genomic gains of 9p24 ( 68 % ) , 2p15 ( 51 % ) , 7q22 ( 32 % ) , 9q34 ( 32 % ) , 12q ( 30 % ) and 18q21 ( 22 % ) were reported .", "label": "", "metadata": {}, "score": "90.33676"}
{"text": "Pegfilgrastim was administered on day 4 and oral aspirin prophylaxis ( 100 mg ) was given daily during the treatment .Maximum - tolerated dose was determined by the number of DLT during the first 2 cycles .", "label": "", "metadata": {}, "score": "90.52272"}
{"text": "Large B - cell lymphoma specified by site .Primary mediastinal large B - cell lymphoma .Primary Mediastinal Large B - cell Lymphoma ( PMBL ) arises in the thymus from thymic B - cells that presents as a mass in the mediastinum [ 1 ] and represent a distinct entity within the germinal center ( GC ) derived high grade DLBCL [ 39 ] .", "label": "", "metadata": {}, "score": "90.99945"}
{"text": "The median age was 65 years .All these patients were heavily pretreated with a median of four prior treatment regimens .Overall response rate ( ORR ) was 19 % . , including 3 complete responses ( CRU + CR ) and 2 partial responses ( PR ) .", "label": "", "metadata": {}, "score": "91.1039"}
{"text": "Lenalidomide dose escalation levels were 15 mg , 20 mg , and 25 mg .All patients received 6 mg pegfilgrastim on day 2 and aspirin prophylaxis .", "label": "", "metadata": {}, "score": "91.11049"}
{"text": "Lancet Oncol .Nabhan C , Smith SM , Helenowski I , et al .Briti J Haematol .Hernandez - Ilizaliturri FJ , Deeb G , Zinzani PL , et al .", "label": "", "metadata": {}, "score": "91.37254"}
{"text": "In the CHOP group , the 5-year survivals for the low - risk and high - risk groups were 56.9 % and 29.2 % , respectively ( . )", "label": "", "metadata": {}, "score": "91.38541"}
{"text": "The median age of the study group at the time of diagnosis was 54 ( range , 16 - 85 yr ) .One hun- dred and thirty - four ( 93.1 % ) patients were classified as DLBCL , not otherwise specified ( NOS ) .", "label": "", "metadata": {}, "score": "91.54053"}
{"text": "When associated to rituximab , results of ORR seems equivalent to lenalidomide alone , with an ORR of 35 % [ 54 ] .However number of CR seems higher as almost all but one responding patients were in CR .", "label": "", "metadata": {}, "score": "91.95349"}
{"text": "Authors ' Contribution .Bertrand Coiffier , Cl\u00e9mentine Sarkozy , and Nicolas Mounier designed the study .Bertrand Coiffier , Cl\u00e9mentine Sarkozy , Nicolas Mounier , Alain Delmer , Achiel Van Hoof , Jean Michel Karsenti , Emmanuel Fleck , Marie Maerevoet , Jean Claude Eisenmann , and Michel Fabbro included patients in the study .", "label": "", "metadata": {}, "score": "93.64743"}
{"text": "12 , pp .1861 - 1874 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .105 , no .", "label": "", "metadata": {}, "score": "94.794464"}
{"text": "The International Prognostic Index ( IPI ) is commonly used to predict patient outcome and to stratify patients into low- and high - risk groups to choose the appropriate therapeutic treatment [ 10 ] .", "label": "", "metadata": {}, "score": "95.123055"}
{"text": "Miller TP , Grogan TM , Dahlberg S , Spier CM , Braziel RM , Banks PM , Foucar K , Kjeldsberg CR , Levy N , Nathwani BN .", "label": "", "metadata": {}, "score": "95.20026"}
{"text": "Indeed , male over 60 years had a median PFS and OS of 55 months and 90.6 months , respectively , whereas women had a median PFS of 90.6 months and median OS was not reached ( Figures 6(a ) and 6(b ) ) .", "label": "", "metadata": {}, "score": "95.2883"}
{"text": "How- ever , the significance of Ki-67 index in other subtypes of DLBCL needs to be explored in a larger cohort .This result is consistent with a previous finding which showed favorable prognosis of patients with low Ki-67 in a sub- group of low IPI ( 13 ) .", "label": "", "metadata": {}, "score": "95.32306"}
{"text": "The 5-year overall survival ( OS ) in the CHOP and R - CHOP groups was 50.4 % and 66.6 % ( . )", "label": "", "metadata": {}, "score": "95.745544"}
{"text": "4 , pp .235 - 242 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .116 , no .", "label": "", "metadata": {}, "score": "95.919846"}
{"text": "The estimated median duration of response was 6.2 months ( range : 0 to 12.8 months ) and median PFS was 4 months ( range : 0 to 14.5 months ) .", "label": "", "metadata": {}, "score": "95.996445"}
{"text": "Ki-67 expression Ki-67 expression varied widely , from 5 % to 100 % , with a median value of 80 % .We examined various cutoff points of Ki-67 expression from the lower to the upper quartile with a rising gradient constructed using 5 % steps ( 60 % , 65 % , 70 % , 75 % , 80 % , 85 % , and 90 % ) .", "label": "", "metadata": {}, "score": "96.02117"}
{"text": "A simplified score termed the age - adjusted IPI ( aaIPI ) , based on the LDH level , Ann Arbor stage , and PS , has been developed and is widely used to direct therapeutic decision in both the younger and elderly patients .", "label": "", "metadata": {}, "score": "97.10412"}
{"text": "Proc Natl Acad Sci U S A. 2003 , 100 ( 17 ) : 9991 - 9996 .10.1073/pnas.1732008100 .PubMed Central View Article PubMed .", "label": "", "metadata": {}, "score": "97.2937"}
{"text": "All authors read and approved the final manuscript .Authors ' Affiliations .Department of Pathology & Laboratory Medicine UCLA - David Geffen UCLA , School of Medicine .", "label": "", "metadata": {}, "score": "97.70747"}
{"text": "116 , no .12 , pp .2040 - 2045 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "99.138016"}
{"text": "94 , no . 9 , pp .1250 - 1258 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "99.17098"}
{"text": "23 , no .18 , pp .4117 - 4126 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "99.46518"}
{"text": "12 , pp .2040 - 2045 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .22 , no .", "label": "", "metadata": {}, "score": "99.91333"}
{"text": "22 , pp .5058 - 5066 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Collaborators .Detail Information .", "label": "", "metadata": {}, "score": "99.94876"}
{"text": "12 , pp .2013 - 2019 , 2008 .View at Google Scholar .6 , no . 1 , pp .103 - 108 , 2011 .", "label": "", "metadata": {}, "score": "100.216354"}
{"text": "3639 - 3646 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .137 , no .4 , pp .", "label": "", "metadata": {}, "score": "100.24556"}
{"text": "105 - 116 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .12 , no .11 , pp .", "label": "", "metadata": {}, "score": "101.36148"}
{"text": "346 , no .4 , pp .235 - 242 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "101.38753"}
{"text": "Bertrand Coiffier and Cl\u00e9mentine Sarkozy wrote the paper .All of the authors reviewed and approved the paper .Acknowledgment .The authors thank S. Bousseta and T. Rabeony for the statistical analysis .", "label": "", "metadata": {}, "score": "101.829666"}
{"text": "Lenalidomide was administered at the dose of 20 mg / daily from day 1 to 21 every 28 days , for four courses , in combination with 375 mg / sqm rituximab on day 1 and day 21 every 28 days for four cycles .", "label": "", "metadata": {}, "score": "103.00614"}
{"text": "9 , no . 2 , pp .105 - 116 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . U.", "label": "", "metadata": {}, "score": "103.482254"}
{"text": "380 - 386 , 1999 .View at Google Scholar \u00b7 View at Scopus .130 , no . 1 , pp .75 - 84 , 2002 .", "label": "", "metadata": {}, "score": "103.71728"}
{"text": "1877 - 1881 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .116 , p. 2871 , 2010 , ASH Annual Meeting Abstracts .", "label": "", "metadata": {}, "score": "104.91881"}
{"text": "CAT Lead the whole manuscript writing WC also wrote and did a review of the literature KK did the tables and drafted the first version of the manuscript .", "label": "", "metadata": {}, "score": "105.40384"}
{"text": "The median EFS and OS in the high Ki-67 group were 0.71 yr ( 95 % CI , 0.424 - 1.001 yr ) and 1.00 yr ( 95 % CI , 0.386 - 1.616 yr ) , respectively .", "label": "", "metadata": {}, "score": "110.7243"}
{"text": "The 5-year OS was 66.5 % , 45.8 % , and 30.0 % for IPI scores 0 , 1 , and 2 ( . )", "label": "", "metadata": {}, "score": "112.22575"}
{"text": "3079 - 3085 , 2000 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus", "label": "", "metadata": {}, "score": "113.071"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .93 , no . 2 , pp .193 - 200 , 2008 .", "label": "", "metadata": {}, "score": "117.10245"}
{"text": "Chen PM , Yang MH , Yu IT , Lin JT , Lin YC , Fan FS , Wang WS , Yen CC , Chiou TJ , Liu JH .", "label": "", "metadata": {}, "score": "118.012184"}
{"text": "Copyright .\u00a9 Tirado et al . ; licensee BioMed Central Ltd. 2012 .This article is published under license to BioMed Central Ltd.Received 7 July 2012 ; Accepted 19 September 2012 .", "label": "", "metadata": {}, "score": "122.376495"}
{"text": "Copyright \u00a9 2012 Ying Huang et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "138.4993"}
{"text": "Copyright \u00a9 2014 Cl\u00e9mentine Sarkozy et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "143.3361"}
{"text": "Copyright \u00a9 2012 Annalisa Chiappella and Umberto Vitolo .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "145.25044"}
{"text": "Org \u00a9 2015 All Rights Researved Princeton , New Jersey 08540 , USA Received 21 September 2013 ; Accepted 17 November 2013 ; Published 16 January 2014 .", "label": "", "metadata": {}, "score": "156.6766"}
